SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
Reduce your risk when donating: see where the money actually goes.
Reduce your risk when donating: see where the money actually goes.
Cite this
Plain text SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE. furp.org, nonprofit organization profile, tax years 2010–2024. https://furp.org/org/sanford-burnham-prebys-medical-discovery-institute-510197108. Retrieved 2026-11-20.
APA furp.org. (n.d.). SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE [Nonprofit organization profile; tax years 2010–2024]. Retrieved November 20, 2026, from https://furp.org/org/sanford-burnham-prebys-medical-discovery-institute-510197108
MLA “SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE.” furp.org, tax years 2010–2024, https://furp.org/org/sanford-burnham-prebys-medical-discovery-institute-510197108. Accessed 20 Nov. 2026.
Retrieved 2026-11-20; covers tax years 2010–2024. Data: furp.org (index © the FURP Alliance; the records are public domain).
Related institution: Sanford Burnham Prebys Medical Discovery Institute Exact
2024 · Form 990 · revenue $114.4M ($117.4M in 2025 dollars) · expenses $116.1M · assets $338.0M
- Also known as
- INSTITUTE
- EIN
- 51-0197108
- Address
- 10901 N TORREY PINES RD, LA JOLLA, CA 92037-1005
- Website
- WWW.SBPDISCOVERY.ORG
- NTEE code
- H92 Biomedicine, Bioengineering Research (Medical Research) published (IRS Business Master File, as H920)
- FURP topic
- abuse: substance · men: issues · science: research education · space: outer · survivor: cancer (from its 990 text; the topic index)
- Exempt type
- 501(c)(3): charitable, religious, educational, scientific or literary (corporation)
- Ruling date
- August 1982 (when the IRS recognized its exemption)
- IRS status
- Exempt (unconditional) (IRS Business Master File) IRS data ↗
- Tax-deductible donations
- Yes: listed in IRS Publication 78 (public charity) Pub 78 ↗
- Foundation status
- Public charity, 509(a)(2)
- Cross-check
- ProPublica Nonprofit Explorer
Mission
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE'S MISSION IS TO ADVANCE THE BIOMEDICAL SCIENCES BY CULTIVATING THE NEXT GENERATION OF SCIENTIFIC LEADERS, PROVIDING MEANINGFUL OPPORTUNITIES FOR RESEARCHERS OF ALL BACKGROUNDS TO LEARN, INNOVATE, AND MAKE BREAKTHROUGH DISCOVERIES THAT IMPROVE HUMAN HEALTH.
Each tax year counts once: when a return was amended, only the latest return for that period is used below (superseded returns stay listed, greyed, under Finances).
People paid by the organization
36 people paid across every filing: current people first, then by total pay from this organization. Organizations counts every nonprofit each person appears on.
| Name | Latest title | Years | Latest year pay | Total pay from here | Organizations |
|---|---|---|---|---|---|
| Kristiina Vuori Md Phd | PROFESSOR | 2010-2024 | $665,672 | $19,562,372 | 3 |
| Carl Ware Phd | CENTER DIRECTOR, IIDC | 2010-2024 | $514,299 | $6,583,448 | 1 |
| Michael Jackson Phd | DRUG DISCOVERY & DEV, SR VP | 2014-2024 | $509,673 | $4,812,103 | 1 |
| David Brenner | CEO & PRESIDENT | 2022-2024 | $1,345,526 | $3,001,736 | 7 |
| Robin Ryan | CFO & TREASURER (THRU 11/15/24) | 2022-2024 | $465,431 | $1,284,524 | 1 |
| Jamey Marth Phd | PROGRAM DIRECTOR | 2022-2024 | $468,110 | $1,020,448 | 1 |
| Adrienne Crown Jd | GENERAL COUNSEL & SECRETARY | 2022-2024 | $361,604 | $1,015,688 | 1 |
| Nicholas Cosford | PROFESSOR & TRUSTEE | 2022-2024 | $384,321 | $1,005,370 | 1 |
| Peter Adams Phd | PROGRAM DIRECTOR | 2024 | $534,247 | $534,247 | 1 |
| Michael Jones | CFO & TREASURER (AS OF OCT 2024) | 2024 | $73,105 | $73,105 | 1 |
| C Randal Mills Phd (former) | FORMER CEO | 2020-2023 | $341,250 | $7,491,594 | 1 |
| Perry Nisen (former) | FORMER CEO | 2014-2018 | $780,458 | $5,007,688 | 1 |
| Daniel Kelly Md (former) | CENTER DIR/SCI DIR AT LK NONA | 2010-2017 | $646,868 | $4,451,586 | 1 |
| Garth Powis Phd (former) | CENTER DIRECTOR | 2014-2020 | $515,516 | $3,849,706 | 1 |
| John C Reed Md Phd (former) | FORMER CEO | 2010-2013 | -$968,401 | $2,959,254 | 2 |
| Ze'Ev Ronai Phd (former) | CENTER DIRECTOR | 2015-2023 | $561,192 | $2,836,375 | 2 |
| Stuart Lipton Md Phd (former) | CENTER DIRECTOR | 2010-2014 | $505,824 | $2,610,514 | 1 |
| Gary F Raisl Edd (former) | EVP/CAO/CFO/TREASURER | 2010-2013 | $507,741 | $2,149,658 | 1 |
| Jorge Moscat Phd (former) | PROGRAM DIRECTOR | 2011-2019 | $486,913 | $1,905,084 | 1 |
| Randal Kaufman Phd (former) | PROGRAM DIRECTOR | 2018-2023 | $477,988 | $1,794,762 | 1 |
| Gary Chessum (former) | CFO (THRU 7/31/2018) | 2015-2018 | $249,273 | $1,466,967 | 1 |
| Gary Raisl Ed D (former) | FORMER EVP/CAO/CFP/TREASURER | 2014-2016 | $365,372 | $1,345,866 | 1 |
| Edward Lewandowski (former) | PROFESSOR | 2016-2017 | $705,980 | $1,248,475 | 1 |
| Louis R Coffman (former) | CAO & CFO | 2018-2020 | $446,066 | $1,152,854 | 3 |
| Paul Laikind Phd (former) | SR VP CBO | 2010-2011 | $528,269 | $915,060 | 3 |
| Amar Duvvur (former) | CFO (THRU 08/22) | 2021-2022 | $493,113 | $914,478 | 1 |
| Edgar Gillenwaters (former) | VP EXTERNAL RELATIONS | 2010-2011 | $335,991 | $693,712 | 1 |
| Margaret Dunbar Jd (former) | SECRETARY/SR DIRECTOR IP | 2011-2013 | $189,852 | $563,261 | 1 |
| Christine Dittmer (former) | CHIEF DEVELOPMENT OFFICER | 2022 | $532,827 | $532,827 | 1 |
| Scott Tocher (former) | CORPORATE SECRETARY (PART YEAR) | 2021-2022 | $246,670 | $448,858 | 1 |
| Chun Jerold Phd (former) | PROFESSOR | 2021 | $413,760 | $413,760 | 1 |
| Blair Blum (former) | SR VP, EXTERNAL RELATIONS | 2010 | $363,794 | $363,794 | 1 |
| Dwight Towler (former) | PROGRAM DIRECTOR | 2013 | $350,759 | $350,759 | 1 |
| Cyril Doucet (former) | VP, ADMIN. AT LAKE NONA | 2012 | $342,982 | $342,982 | 1 |
| Tariq Rana Phd (former) | PROGRAM DIRECTOR | 2011 | $327,304 | $327,304 | 1 |
| Fred Levine Md Phd (former) | TRUSTEE/CENTER DIRECTOR | 2010 | $244,495 | $244,495 | 1 |
Officers and directors, no compensation reported
69 people listed on the returns with $0 (or no amount) in every compensation column: current people first. Hours are as filed on the latest return each person appears on.
| Name | Latest title | Years | Hrs/wk (latest) | Compensation | Organizations |
|---|---|---|---|---|---|
| Donald Kearns | CHAIR | 2021-2024 | 1 | $0 reported | 7 |
| William Gerhart | TRUSTEE | 2013-2024 | 1 | $0 reported | 1 |
| Daniel J Epstein | TRUSTEE | 2011-2024 | 1 | $0 reported | 1 |
| David L Szekeres Jd | TRUSTEE | 2019-2024 | 1 | $0 reported | 1 |
| David W Down | TRUSTEE | 2013-2024 | 1 | $0 reported | 8 |
| Douglas H Obenshain | TRUSTEE | 2010-2024 | 1 | $0 reported | 1 |
| Katherine Chapin | TRUSTEE | 2020-2024 | 1 | $0 reported | 1 |
| Kazumi Shiosaki Phd | TRUSTEE | 2016-2024 | 1 | $0 reported | 1 |
| Lonna J Williams Stolper | TRUSTEE | 2023-2024 | 1 | $0 reported | 1 |
| Lori Moore | VICE CHAIR | 2023-2024 | 1 | $0 reported | 1 |
| Michael R Cunningham | TRUSTEE (THRU 11/1/24) | 2023-2024 | 1 | $0 reported | 1 |
| Stuart Tanz | TRUSTEE | 2010-2024 | 1 | $0 reported | 1 |
| Ted Roth | TRUSTEE | 2023-2024 | 1 | $0 reported | 6 |
| William Roper | TRUSTEE | 2018-2024 | 1 | $0 reported | 1 |
| James C Blair Phd (former) | TRUSTEE (PART YEAR) | 2012-2023 | 1 | $0 reported | 1 |
| James M Myers (former) | TRUSTEE (PART YEAR) | 2016-2023 | 1 | $0 reported | 1 |
| James E Jardon Ii (former) | TRUSTEE (PART YEAR) | 2021-2022 | 1 | $0 reported | 1 |
| Karen S Haynes (former) | TRUSTEE (PART YEAR) | 2019-2022 | 1 | $0 reported | 4 |
| Matthew Browne (former) | TRUSTEE (PART YEAR) | 2018-2022 | 1 | $0 reported | 1 |
| Anna Barker Phd (former) | TRUSTEE (PART YEAR) | 2017-2021 | 1 | $0 reported | 1 |
| Henry Nordoff (former) | TRUSTEE (PART YEAR) | 2012-2021 | 1 | $0 reported | 1 |
| Dan Epstein (former) | TRUSTEE | 2019-2020 | 1 | $0 reported | 2 |
| Knox Bell (former) | CORPORATE SECRETARY | 2014-2020 | 2 | $0 reported | 2 |
| Donald Kerns Phd (former) | TRUSTEE | 2019-2020 | 1 | $0 reported | 1 |
| James Jardon (former) | TRUSTEE | 2011-2020 | 1 | $0 reported | 1 |
| Peter Seidler (former) | TRUSTEE (PART YEAR) | 2017-2020 | 1 | $0 reported | 1 |
| Jeanne Herberger (former) | TRUSTEE (PART YEAR) | 2010-2019 | 1 | $0 reported | 1 |
| Alan Gleicher (former) | TRUSTEE (PART YEAR) | 2010-2018 | 1 | $0 reported | 1 |
| Donald Rosenberg (former) | TRUSTEE (PART YEAR) | 2016-2018 | 1 | $0 reported | 1 |
| David Szekered (former) | TRUSTEE | 2018 | 1 | $0 reported | 1 |
| Carol Gallagher (former) | TRUSTEE (PART YEAR) | 2015-2017 | 1 | $0 reported | 3 |
| Greg Lucier (former) | TRUSTEE (PART YEAR) | 2010-2017 | 1 | $0 reported | 2 |
| Wainwright Fishburn (former) | TRUSTEE (PART YEAR) | 2013-2017 | 1 | $0 reported | 2 |
| Luder Whitlock (former) | TRUSTEE (PART YEAR) | 2013-2017 | 1 | $0 reported | 1 |
| Lorenzo Berho (former) | TRUSTEE (PART YEAR) | 2011-2017 | 1 | $0 reported | 1 |
| Donald Jernigan (former) | TRUSTEE (PART YEAR) | 2014-2017 | 1 | $0 reported | 1 |
| Edward Schulak (former) | TRUSTEE (PART YEAR) | 2014-2017 | 1 | $0 reported | 1 |
| Bernard Machen (former) | TRUSTEE (PART YEAR) | 2012-2016 | 1 | $0 reported | 1 |
| Rasesh Thakkar (former) | TRUSTEE (PART YEAR) | 2013-2016 | 1 | $0 reported | 1 |
| Patrick Geraghty (former) | TRUSTEE (PART YEAR) | 2012-2016 | 1 | $0 reported | 1 |
| Doug Manchester (former) | TRUSTEE (PART YEAR) | 2015-2016 | 1 | $0 reported | 1 |
| Pauline Foster (former) | TRUSTEE (PART YEAR) | 2010-2016 | 1 | $0 reported | 1 |
| Andrew Viterbi (former) | TRUSTEE (PART YEAR) | 2010-2014 | 1 | $0 reported | 2 |
| Peter Preuss (former) | TRUSTEE (PART YEAR) | 2010-2014 | 1 | $0 reported | 5 |
| Brent Jacobs (former) | TRUSTEE (PART YEAR) | 2010-2014 | 1 | $0 reported | 2 |
| Papa Doug Manchester (former) | TRUSTEE | 2014 | 1 | $0 reported | 1 |
| Allen Weiss (former) | TRUSTEE (PART YEAR) | 2011-2014 | 1 | $0 reported | 1 |
| Gayle Wilson (former) | TRUSTEE (PART YEAR) | 2010-2014 | 1 | $0 reported | 1 |
| Shehan Dissanayake (former) | TRUSTEE | 2011-2013 | 1 | $0 reported | 1 |
| Wain Fishburn (former) | TRUSTEE/CHAIRMAN | 2010-2012 | 1 | $0 reported | 2 |
| Duane Roth (former) | TRUSTEE | 2012 | 1 | $0 reported | 5 |
| Robert Lauer (former) | TRUSTEE | 2010-2012 | 1 | $0 reported | 1 |
| Nicolas Nierenberg (former) | TRUSTEE | 2010-2012 | 1 | $0 reported | 1 |
| Jan Tuttleman (former) | TRUSTEE | 2010-2012 | 1 | $0 reported | 1 |
| David F Hale (former) | TRUSTEE | 2010-2011 | 1 | $0 reported | 11 |
| Arthur Brody (former) | TRUSTEE | 2010-2011 | 1 | $0 reported | 1 |
| Robert Mandell (former) | TRUSTEE | 2010-2011 | 1 | $0 reported | 1 |
| Duanne Roth (former) | TRUSTEE | 2011 | 1 | $0 reported | 1 |
| Barbara Warren (former) | TRUSTEE | 2010-2011 | 1 | $0 reported | 1 |
| Diane Winokur (former) | TRUSTEE | 2010-2011 | 1 | $0 reported | 1 |
| Malin Burnham (former) | TRUSTEE | 2010 | 1 | $0 reported | 15 |
| Bridgette Bren (former) | TRUSTEE | 2010 | 1 | $0 reported | 1 |
| Shehan Dissanyake (former) | TRUSTEE | 2010 | 1 | $0 reported | 1 |
| Jeannie Fontana (former) | TRUSTEE | 2010 | 1 | $0 reported | 1 |
| Jim Jardon (former) | TRUSTEE | 2010 | 1 | $0 reported | 1 |
| Sheila Lipinsky (former) | TRUSTEE | 2010 | 1 | $0 reported | 1 |
| Douglas Manchester (former) | TRUSTEE | 2010 | 1 | $0 reported | 1 |
| Alan Weiss (former) | TRUSTEE | 2010 | 1 | $0 reported | 1 |
| Ken Woolcott (former) | TRUSTEE | 2010 | 1 | $0 reported | 1 |
People by year
2024 · 24 people listed · 10 paid, $5.3M · 611 employees · 14 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| DAVID BRENNER | CEO & PRESIDENT | 50 | $994,322 | $0 | $351,204 | $1,345,526 | 7 |
| KRISTIINA VUORI MD PHD | PROFESSOR | 50 | $602,266 | $0 | $63,406 | $665,672 | 3 |
| PETER ADAMS PHD | PROGRAM DIRECTOR | 50 | $450,347 | $0 | $83,900 | $534,247 | 1 |
| CARL WARE PHD | CENTER DIRECTOR, IIDC | 50 | $449,559 | $0 | $64,740 | $514,299 | 1 |
| MICHAEL JACKSON PHD | DRUG DISCOVERY & DEV, SR VP | 50 | $443,835 | $0 | $65,838 | $509,673 | 1 |
| JAMEY MARTH PHD | PROGRAM DIRECTOR | 50 | $399,446 | $0 | $68,664 | $468,110 | 1 |
| ROBIN RYAN | CFO & TREASURER (THRU 11/15/24) | 50 | $414,770 | $0 | $50,661 | $465,431 | 1 |
| NICHOLAS COSFORD | PROFESSOR & TRUSTEE | 50 | $305,473 | $0 | $78,848 | $384,321 | 1 |
| ADRIENNE CROWN JD | GENERAL COUNSEL & SECRETARY | 50 | $313,425 | $0 | $48,179 | $361,604 | 1 |
| MICHAEL JONES | CFO & TREASURER (AS OF OCT 2024) | 50 | $67,222 | $0 | $5,883 | $73,105 | 1 |
| DONALD KEARNS | CHAIR | 1 | $0 | $0 | $0 | $0 | 7 |
| LORI MOORE | VICE CHAIR | 1 | $0 | $0 | $0 | $0 | 1 |
| MICHAEL R CUNNINGHAM | TRUSTEE (THRU 11/1/24) | 1 | $0 | $0 | $0 | $0 | 1 |
| DAVID W DOWN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 8 |
| DANIEL J EPSTEIN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| WILLIAM GERHART | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| DOUGLAS H OBENSHAIN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| WILLIAM ROPER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| TED ROTH | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 6 |
| KAZUMI SHIOSAKI PHD | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| LONNA J WILLIAMS STOLPER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| DAVID L SZEKERES JD | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| STUART TANZ | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| KATHERINE CHAPIN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
2023 · 26 people listed · 10 paid, $5.6M · 594 employees · 16 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| DAVID BRENNER MD | CEO AND PRESIDENT | 50 | $984,345 | $0 | $327,443 | $1,311,788 | 7 |
| KRISTIINA VUORI MD PHD | PROFESSOR | 50 | $601,208 | $0 | $60,610 | $661,818 | 3 |
| ZE'EV RONAI PHD | CENTER DIRECTOR | 50 | $497,532 | $0 | $63,660 | $561,192 | 2 |
| CARL WARE PHD | CENTER DIRECTOR, IIDC | 50 | $454,389 | $0 | $63,702 | $518,091 | 1 |
| ROBIN RYAN | CFO & TREASURER | 50 | $458,690 | $0 | $48,299 | $506,989 | 1 |
| MICHAEL JACKSON PHD | DRUG DISCOVERY & DEV, SR VP | 50 | $447,238 | $0 | $58,573 | $505,811 | 1 |
| RANDAL KAUFMAN PHD | PROGRAM DIRECTOR | 50 | $402,033 | $0 | $75,955 | $477,988 | 1 |
| ADRIENNE CROWN JD | GENERAL COUNSEL & SECRETARY | 50 | $360,490 | $0 | $48,673 | $409,163 | 1 |
| C RANDAL MILLS PHD | FORMER CEO | 0 | $341,250 | $0 | $0 | $341,250 | 1 |
| NICHOLAS COSFORD | PROFESSOR & TRUSTEE | 50 | $244,128 | $0 | $68,484 | $312,612 | 1 |
| DONALD B KEARNS MD | VICE CHAIRMAN | 1 | $0 | $0 | $0 | $0 | 7 |
| WILLIAM GERHART | CHAIRMAN | 1 | $0 | $0 | $0 | $0 | 1 |
| DANIEL J EPSTEIN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| DAVID L SZEKERES JD | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| DAVID W DOWN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 8 |
| DOUGLAS H OBENSHAIN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| JAMES C BLAIR PHD | TRUSTEE (PART YEAR) | 1 | $0 | $0 | $0 | $0 | 1 |
| JAMES M MYERS | TRUSTEE (PART YEAR) | 1 | $0 | $0 | $0 | $0 | 1 |
| KATHERINE CHAPIN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| KAZUMI SHIOSAKI PHD | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| LONNA J WILLIAMS STOLPER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| LORI MOORE | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| MICHAEL R CUNNINGHAM | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| STUART A TANZ | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| TED ROTH | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 6 |
| WILLIAM A ROPER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
2022 · 27 people listed · 12 paid, $9.8M · 624 employees · 15 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| C RANDAL MILLS PHD | FORMER CEO | 0 | $4,979,417 | $0 | $46,642 | $5,026,059 | 1 |
| KRISTIINA VUORI MD PHD | PROFESSOR & FORMER PRESIDENT | 50 | $710,798 | $0 | $55,967 | $766,765 | 3 |
| JAMEY MARTH PHD | PROGRAM DIRECTOR | 50 | $494,296 | $0 | $58,042 | $552,338 | 1 |
| CHRISTINE DITTMER | CHIEF DEVELOPMENT OFFICER | 50 | $500,215 | $0 | $32,612 | $532,827 | 1 |
| ZE'EV RONAI PHD | CENTER DIRECTOR | 50 | $440,033 | $0 | $67,963 | $507,996 | 2 |
| CARL WARE PHD | CENTER DIRECTOR, IIDC | 50 | $445,990 | $0 | $58,835 | $504,825 | 1 |
| AMAR DUVVUR | CFO (THRU 08/22) | 50 | $463,528 | $0 | $29,585 | $493,113 | 1 |
| DAVID BRENNER MD | CEO AND PRESIDENT (AS OF 09/2022) | 50 | $252,575 | $0 | $91,847 | $344,422 | 7 |
| ROBIN RYAN | CFO & TREASURER | 50 | $272,541 | $0 | $39,563 | $312,104 | 1 |
| NICHOLAS COSFORD | PROFESSOR & TRUSTEE | 50 | $243,409 | $0 | $65,028 | $308,437 | 1 |
| SCOTT TOCHER | CORPORATE SECRETARY (PART YEAR) | 50 | $236,687 | $0 | $9,983 | $246,670 | 1 |
| ADRIENNE CROWN | GENERAL COUNSEL & SECRETARY | 50 | $213,256 | $0 | $31,665 | $244,921 | 1 |
| DONALD B KEARNS PHD | VICE CHAIRMAN | 1 | $0 | $0 | $0 | $0 | 7 |
| WILLIAM GERHART | CHAIRMAN | 1 | $0 | $0 | $0 | $0 | 1 |
| DANIEL J EPSTEIN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| DAVID L SZEKERES | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| DAVID W DOWN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 8 |
| DOUGLAS H OBENSHAIN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| JAMES C BLAIR PHD | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| JAMES E JARDON II | TRUSTEE (PART YEAR) | 1 | $0 | $0 | $0 | $0 | 1 |
| JAMES M MYERS | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| KAREN S HAYNES | TRUSTEE (PART YEAR) | 1 | $0 | $0 | $0 | $0 | 4 |
| KATHERINE CHAPIN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| KAZUMI SHIOSAKI PHD | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| MATTHEW BROWNE | TRUSTEE (PART YEAR) | 1 | $0 | $0 | $0 | $0 | 1 |
| STUART A TANZ | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| WILLIAM A ROPER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
2021 · 26 people listed · 9 paid, $5.5M · 645 employees · 15 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| C RANDAL MILLS PHD | CEO (PART YEAR) | 50 | $1,190,319 | $0 | $268,556 | $1,458,875 | 1 |
| KRISTIINA VUORI MD PHD | PRESIDENT | 50 | $986,151 | $0 | $53,567 | $1,039,718 | 3 |
| ZE'EV RONAI PHD | CENTER DIRECTOR | 50 | $449,551 | $0 | $68,556 | $518,107 | 2 |
| MICHAEL JACKSON PHD | DRUG DISCOVERY & DEV, SR VP | 50 | $448,253 | $0 | $60,058 | $508,311 | 1 |
| CARL WARE PHD | CENTER DIRECTOR, IIDC | 50 | $450,942 | $0 | $45,465 | $496,407 | 1 |
| RANDAL KAUFMAN PHD | PROGRAM DIRECTOR | 50 | $378,919 | $0 | $65,980 | $444,899 | 1 |
| AMAR DUVVUR | CFO | 50 | $412,421 | $0 | $8,944 | $421,365 | 1 |
| CHUN JEROLD PHD | PROFESSOR | 50 | $360,136 | $0 | $53,624 | $413,760 | 1 |
| SCOTT TOCHER | GENERAL COUNSEL & CORPORATE SECRETARY | 50 | $194,719 | $0 | $7,469 | $202,188 | 1 |
| JAMES C BLAIR PHD | CHAIRMAN | 1 | $0 | $0 | $0 | $0 | 1 |
| WILLIAM GERHART | VICE CHAIRMAN | 1 | $0 | $0 | $0 | $0 | 1 |
| ANNA BARKER PHD | TRUSTEE (PART YEAR) | 1 | $0 | $0 | $0 | $0 | 1 |
| DANIEL J EPSTEIN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| DAVID L SZEKERES | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| DAVID W DOWN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 8 |
| DONALD B KEARNS PHD | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 7 |
| DOUGLAS H OBENSHAIN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| HENRY NORDOFF | TRUSTEE (PART YEAR) | 1 | $0 | $0 | $0 | $0 | 1 |
| JAMES E JARDON II | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| JAMES M MYERS | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| KAREN S HAYNES | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 4 |
| KATHERINE CHAPIN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| KAZUMI SHIOSAKI PHD | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| MATTHEW BROWNE | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| STUART A TANZ | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| WILLIAM A ROPER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
2020 · 27 people listed · 8 paid, $6.1M · 696 employees · 19 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| KRISTIINA VUORI MD PHD | PRESIDENT | 50 | $2,599,463 | $0 | $53,106 | $2,652,569 | 3 |
| C RANDAL MILLS PHD | CEO | 50 | $564,836 | $0 | $100,574 | $665,410 | 1 |
| GARTH POWIS PHD | CENTER DIRECTOR | 50 | $464,625 | $0 | $50,891 | $515,516 | 1 |
| MICHAEL JACKSON PHD | DRUG DISCOVERY & DEV, SR VP | 50 | $418,564 | $0 | $56,754 | $475,318 | 1 |
| CARL WARE PHD | CENTER DIRECTOR, IIDC | 50 | $405,773 | $0 | $55,843 | $461,616 | 1 |
| RANDAL KAUFMAN PHD | PROGRAM DIRECTOR | 50 | $388,639 | $0 | $64,168 | $452,807 | 1 |
| LOUIS COFFMAN | CAO & CFO | 50 | $390,278 | $0 | $55,788 | $446,066 | 3 |
| ZE'EV RONAI PHD | PROGRAM DIRECTOR | 50 | $354,747 | $0 | $68,113 | $422,860 | 2 |
| ANNA BARKER PHD | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| DAN EPSTEIN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 2 |
| DAVID DOWN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 8 |
| DAVID SZEKERES | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| DONALD KERNS PHD | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| DOUGLAS OBENSHAIN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| HENRY NORDOFF | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| JAMES BLAIR PHD | CHAIRMAN | 1 | $0 | $0 | $0 | $0 | 1 |
| JAMES JARDON | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| JAMES MYERS | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| KAREN HAYNES PHD | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 4 |
| KATHERINE CHAPIN | TRUSTEE (PART YEAR) | 1 | $0 | $0 | $0 | $0 | 1 |
| KAZUMI SHIOSAKI PHD | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| MATTHEW BROWNE | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| PETER SEIDLER | TRUSTEE (PART YEAR) | 1 | $0 | $0 | $0 | $0 | 1 |
| STUART TANZ | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| WILLIAM GERHART | VICE CHAIRMAN | 1 | $0 | $0 | $0 | $0 | 1 |
| WILLIAM ROPER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| KNOX BELL | CORPORATE SECRETARY | 2 | $0 | $0 | $0 | $0 | 2 |
2019 · 26 people listed · 7 paid, $4.3M · 779 employees · 19 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| KRISTIINA VUORI MD PHD | PRESIDENT | 50 | $1,022,617 | $0 | $350,424 | $1,373,041 | 3 |
| GARTH POWIS PHD | CENTER DIRECTOR | 50 | $504,532 | $0 | $53,042 | $557,574 | 1 |
| MICHAEL JACKSON PHD | DRUG DISCOVERY & DEV, SR VP | 50 | $432,356 | $0 | $58,766 | $491,122 | 1 |
| CARL WARE PHD | CENTER DIRECTOR, IIDC | 50 | $437,966 | $0 | $52,965 | $490,931 | 1 |
| JORGE MOSCAT PHD | PROGRAM DIRECTOR | 50 | $431,058 | $0 | $55,855 | $486,913 | 1 |
| LOUIS COFFMAN | CAO & CFO | 50 | $434,723 | $0 | $40,656 | $475,379 | 3 |
| ZE'EV RONAI PHD | PROGRAM DIRECTOR | 50 | $383,277 | $0 | $65,401 | $448,678 | 2 |
| DOUGLAS OBENSHAIN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| DAVID DOWN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 8 |
| WILLIAM GERHART | VICE CHAIRMAN | 1 | $0 | $0 | $0 | $0 | 1 |
| STUART TANZ | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| JAMES JARDON | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| JAMES MYERS | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| KAZUMI SHIOSAKI PHD | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| PETER SEIDLER | TRUSTEE (PART YEAR) | 1 | $0 | $0 | $0 | $0 | 1 |
| DAN EPSTEIN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 2 |
| WILLIAM ROPER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| MATTHEW BROWNE | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| DAVID SZEKERES | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| KAREN HAYNES PHD | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 4 |
| DONALD KERNS PHD | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| JEANNE HERBERGER | TRUSTEE (PART YEAR) | 1 | $0 | $0 | $0 | $0 | 1 |
| ANNA BARKER PHD | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| HENRY NORDOFF | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| JAMES BLAIR PHD | CHAIRMAN | 1 | $0 | $0 | $0 | $0 | 1 |
| KNOX BELL | CORPORATE SECRETARY | 2 | $0 | $0 | $0 | $0 | 2 |
2018 · 28 people listed · 9 paid, $4.9M · 911 employees · 19 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| KRISTIINA VUORI MD PHD | PRESIDENT | 50 | $1,010,709 | $0 | $345,320 | $1,356,029 | 3 |
| PERRY NISEN | FORMER CEO | 50 | $780,458 | $0 | $0 | $780,458 | 1 |
| GARTH POWIS PHD | CENTER DIRECTOR | 50 | $504,465 | $0 | $47,628 | $552,093 | 1 |
| MICHAEL JACKSON PHD | DRUG DISCOVERY & DEV, SR VP | 50 | $439,813 | $0 | $58,021 | $497,834 | 1 |
| CARL WARE PHD | CENTER DIRECTOR, IIDC | 50 | $404,789 | $0 | $47,395 | $452,184 | 1 |
| RANDAL KAUFMAN PHD | PROGRAM DIRECTOR | 50 | $360,737 | $0 | $58,331 | $419,068 | 1 |
| JORGE MOSCAT PHD | PROGRAM DIRECTOR | 50 | $350,276 | $0 | $57,743 | $408,019 | 1 |
| GARY CHESSUM | CFO (THRU 7/31/2018) | 50 | $218,557 | $0 | $30,716 | $249,273 | 1 |
| LOUIS COFFMAN | CAO & CFO | 50 | $207,752 | $0 | $23,657 | $231,409 | 3 |
| DOUGLAS OBENSHAIN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| DAVID DOWN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 8 |
| WILLIAM GERHART | VICE CHAIRMAN | 1 | $0 | $0 | $0 | $0 | 1 |
| ALAN GLEICHER | TRUSTEE (PART YEAR) | 1 | $0 | $0 | $0 | $0 | 1 |
| JEANNE HERBERGER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| STUART TANZ | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| JAMES JARDON | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| DONALD ROSENBERG | TRUSTEE (PART YEAR) | 1 | $0 | $0 | $0 | $0 | 1 |
| JAMES MYERS | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| KAZUMI SHIOSAKI | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| PETER SEIDLER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| ANNA BARKER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| DANIEL EPSTEIN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| HENRY NORDOFF | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| JAMES BLAIR | CHAIR | 1 | $0 | $0 | $0 | $0 | 1 |
| WILLIAM ROPER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| MATTHEW BROWNE | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| DAVID SZEKERED | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| KNOX BELL | CORPORATE SECRETARY | 2 | $0 | $0 | $0 | $0 | 2 |
2017 · 31 people listed · 8 paid, $5.3M · 969 employees · 22 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| KRISTIINA VUORI MD PHD | PRESIDENT | 50 | $969,097 | $0 | $343,074 | $1,312,171 | 3 |
| PERRY NISEN MD PHD | CEO (PART YEAR) | 50 | $1,205,646 | $0 | -$431,901 | $773,745 | 1 |
| EDWARD LEWANDOWSKI | PROFESSOR | 50 | $652,124 | $0 | $53,856 | $705,980 | 1 |
| DANIEL KELLY MD | CENTER DIR/SCI DIR AT LK NONA | 50 | $602,402 | $0 | $44,466 | $646,868 | 1 |
| GARTH POWIS PHD | CENTER DIRECTOR | 50 | $504,423 | $0 | $44,881 | $549,304 | 1 |
| MICHAEL JACKSON PHD | DRUG DISCOVERY & DEV, SR VP | 50 | $388,597 | $0 | $54,059 | $442,656 | 1 |
| CARL WARE PHD | CENTER DIRECTOR, IIDC | 50 | $393,349 | $0 | $44,954 | $438,303 | 1 |
| GARY CHESSUM | CFO | 50 | $376,444 | $0 | $54,366 | $430,810 | 1 |
| DOUGLAS OBENSHAIN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| DAVID DOWN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 8 |
| WILLIAM GERHART | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| LUDER WHITLOCK | TRUSTEE (PART YEAR) | 1 | $0 | $0 | $0 | $0 | 1 |
| LORENZO BERHO | TRUSTEE (PART YEAR) | 1 | $0 | $0 | $0 | $0 | 1 |
| WAINWRIGHT FISHBURN | TRUSTEE (PART YEAR) | 1 | $0 | $0 | $0 | $0 | 2 |
| ALAN GLEICHER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| JEANNE HERBERGER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| DONALD JERNIGAN | TRUSTEE (PART YEAR) | 1 | $0 | $0 | $0 | $0 | 1 |
| EDWARD SCHULAK | TRUSTEE (PART YEAR) | 1 | $0 | $0 | $0 | $0 | 1 |
| STUART TANZ | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| CAROL GALLAGHER | TRUSTEE (PART YEAR) | 1 | $0 | $0 | $0 | $0 | 3 |
| GREG LUCIER | TRUSTEE (PART YEAR) | 1 | $0 | $0 | $0 | $0 | 2 |
| JAMES JARDON | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| DONALD ROSENBERG | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| JAMES MYERS | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| KAZUMI SHIOSAKI | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| PETER SEIDLER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| ANNA BARKER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| DANIEL EPSTEIN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| HENRY NORDOFF | CHAIRMAN | 1 | $0 | $0 | $0 | $0 | 1 |
| JAMES BLAIR | VICE CHAIRMAN | 1 | $0 | $0 | $0 | $0 | 1 |
| KNOX BELL | CORPORATE SECRETARY | 2 | $0 | $0 | $0 | $0 | 2 |
2016 · 35 people listed · 9 paid, $6.1M · 983 employees · 25 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| KRISTIINA VUORI MD PHD | PRESIDENT | 50 | $886,682 | $0 | $565,924 | $1,452,606 | 3 |
| PERRY NISEN MD PHD | CEO | 50 | $1,115,133 | $0 | $122,179 | $1,237,312 | 1 |
| DANIEL KELLY MD | CNTR DIR/SCI DIR AT LK NONA | 50 | $502,023 | $0 | $50,731 | $552,754 | 1 |
| GARTH POWIS PHD | CENTER DIRECTOR | 50 | $503,978 | $0 | $42,359 | $546,337 | 1 |
| EDWARD LEWANDOWSKI | PROFESSOR | 50 | $518,581 | $0 | $23,914 | $542,495 | 1 |
| MICHAEL JACKSON PHD | DRUG DISCOVERY & DEV, SR VP | 50 | $433,071 | $0 | $50,455 | $483,526 | 1 |
| CARL WARE PHD | CENTER DIRECTOR, IIDC | 50 | $417,535 | $0 | $42,616 | $460,151 | 1 |
| GARY CHESSUM | CFO | 50 | $418,910 | $0 | $36,262 | $455,172 | 1 |
| GARY RAISL ED D | FORMER EVP/CAO/CFP/TREASURER | 0 | $365,372 | $0 | $0 | $365,372 | 1 |
| DOUGLAS OBENSHAIN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| BERNARD MACHEN | TRUSTEE (PART YEAR) | 1 | $0 | $0 | $0 | $0 | 1 |
| DAVID DOWN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 8 |
| WILLIAM GERHART | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| RASESH THAKKAR | TRUSTEE (PART YEAR) | 1 | $0 | $0 | $0 | $0 | 1 |
| LUDER WHITLOCK | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| LORENZO BERHO | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| DANIEL EPSTEIN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| WAINWRIGHT FISHBURN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 2 |
| PATRICK GERAGHTY | TRUSTEE (PART YEAR) | 1 | $0 | $0 | $0 | $0 | 1 |
| ALAN GLEICHER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| JEANNE HERBERGER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| DONALD JERNIGAN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| DOUG MANCHESTER | TRUSTEE (PART YEAR) | 1 | $0 | $0 | $0 | $0 | 1 |
| EDWARD SCHULAK | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| STUART TANZ | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| CAROL GALLAGHER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 3 |
| GREG LUCIER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 2 |
| JAMES JARDON | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| DONALD ROSENBERG | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| JAMES MYERS | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| KAZUMI SHIOSAKI | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| HENRY NORDOFF | CHAIRMAN | 1 | $0 | $0 | $0 | $0 | 1 |
| JAMES BLAIR | VICE CHAIR | 1 | $0 | $0 | $0 | $0 | 1 |
| PAULINE FOSTER | TRUSTEE (PART YEAR) | 1 | $0 | $0 | $0 | $0 | 1 |
| KNOX BELL | CORPORATE SECRETARY | 2 | $0 | $0 | $0 | $0 | 2 |
2015 · 31 people listed · 9 paid, $7.6M · 1,015 employees · 22 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| KRISTIINA VUORI MD PHD | PRESIDENT | 50 | $2,666,889 | $0 | $112,645 | $2,779,534 | 3 |
| PERRY NISEN MD PHD | CEO | 50 | $1,111,930 | $0 | $336,252 | $1,448,182 | 1 |
| GARTH POWIS PHD | CENTER DIRECTOR | 50 | $548,622 | $0 | $37,785 | $586,407 | 1 |
| DANIEL KELLY MD | CNTR DIR/SCI DIR AT LK NONA | 50 | $537,617 | $0 | $45,718 | $583,335 | 1 |
| MICHAEL JACKSON PHD | DRUG DISCOVERY & DEV, SR VP | 50 | $456,626 | $0 | $43,695 | $500,321 | 1 |
| GARY RAISL ED D | EVP/CAO/CFO/TREAS (OUTGOING) | 50 | $463,475 | $0 | $34,830 | $498,305 | 1 |
| CARL WARE PHD | CENTER DIRECTOR, IIDC | 50 | $439,854 | $0 | $39,071 | $478,925 | 1 |
| ZE'EV RONAI | SCIENTIFIC DIRECTOR | 50 | $333,540 | $0 | $44,002 | $377,542 | 2 |
| GARY CHESSUM | CFO | 50 | $325,857 | $0 | $5,855 | $331,712 | 1 |
| DAVID DOWN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 8 |
| WILLIAM GERHART | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| RASESH THAKKAR | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| LUDER WHITLOCK | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| LORENZO BERHO | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| JAMES BLAIR | VICE CHAIRMAN | 1 | $0 | $0 | $0 | $0 | 1 |
| DANIEL EPSTEIN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| WAINWRIGHT FISHBURN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 2 |
| PAULINE FOSTER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| PATRICK GERAGHTY | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| ALAN GLEICHER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| JEANNE HERBERGER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| DONALD JERNIGAN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| DOUG MANCHESTER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| EDWARD SCHULAK | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| STUART TANZ | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| CAROL GALLAGHER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 3 |
| GREG LUCIER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 2 |
| HENRY NORDOFF | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| DOUGLAS OBENSHAIN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| BERNARD MACHEN | CHAIRMAN | 1 | $0 | $0 | $0 | $0 | 1 |
| KNOX BELL | SECRETARY | 2 | $0 | $0 | $0 | $0 | 2 |
2014 · 34 people listed · 8 paid, $5.1M · 1,000 employees · 20 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| KRISTIINA VUORI MD PHD | INTERIM CEO/PRESIDENT | 50 | $1,124,006 | $0 | $336,919 | $1,460,925 | 3 |
| PERRY NISEN MD PHD | CEO | 50 | $563,569 | $0 | $204,422 | $767,991 | 1 |
| GARTH POWIS PHD | CENTER DIRECTOR | 50 | $501,420 | $0 | $41,055 | $542,475 | 1 |
| DANIEL KELLY MD | CNTR DIR/SCI DIR AT LK NONA | 50 | $475,364 | $0 | $47,712 | $523,076 | 1 |
| STUART LIPTON MD PHD | CENTER DIRECTOR | 50 | $455,233 | $0 | $50,591 | $505,824 | 1 |
| GARY RAISL ED D | EVP/CAO/CFO/TREASURER | 50 | $439,576 | $0 | $42,613 | $482,189 | 1 |
| CARL WARE PHD | CENTER DIRECTOR, IIDC | 50 | $359,036 | $0 | $39,136 | $398,172 | 1 |
| MICHAEL JACKSON PHD | DRUG DISCOVERY & DEV, SR VP | 50 | $354,616 | $0 | $42,915 | $397,531 | 1 |
| DAVID DOWN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 8 |
| WILLIAM GERHART | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| RASESH THAKKAR | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| LUDER WHITLOCK | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| LORENZO BERHO | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| JAMES BLAIR | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| DANIEL EPSTEIN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| WAINWRIGHT FISHBURN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 2 |
| PAULINE FOSTER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| PATRICK GERAGHTY | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| ALAN GLEICHER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| JEANNE HERBERGER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| DONALD JERNIGAN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| PAPA DOUG MANCHESTER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| EDWARD SCHULAK | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| GREG LUCIER | CHAIRMAN | 1 | $0 | $0 | $0 | $0 | 2 |
| HENRY NORDOFF | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| DOUGLAS OBENSHAIN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| BERNARD MACHEN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| BRENT JACOBS | TRUSTEE (PART YEAR) | 1 | $0 | $0 | $0 | $0 | 2 |
| JAMES JARDON | TRUSTEE (PART YEAR) | 1 | $0 | $0 | $0 | $0 | 1 |
| PETER PREUSS | TRUSTEE (PART YEAR) | 1 | $0 | $0 | $0 | $0 | 5 |
| ANDREW VITERBI | TRUSTEE (PART YEAR) | 1 | $0 | $0 | $0 | $0 | 2 |
| ALLEN WEISS | TRUSTEE (PART YEAR) | 1 | $0 | $0 | $0 | $0 | 1 |
| GAYLE WILSON | TRUSTEE (PART YEAR) | 1 | $0 | $0 | $0 | $0 | 1 |
| KNOX BELL | SECRETARY | 2 | $0 | $0 | $0 | $0 | 2 |
2013 · 32 people listed · 9 paid, $2.9M · 1,067 employees · 23 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| KRISTIINA VUORI MD PHD | INTERIM CEO/PRESIDENT | 50 | $639,237 | $0 | $337,141 | $976,378 | 3 |
| STUART LIPTON MD PHD | CENTER DIRECTOR | 50 | $466,329 | $0 | $67,015 | $533,344 | 1 |
| DANIEL KELLY MD | CNTR DIR./SCI. DIR. AT LK NONA | 50 | $474,889 | $0 | $53,514 | $528,403 | 1 |
| GARY F RAISL EDD | EVP/CAO/CFO/TREASURER | 50 | $450,474 | $0 | $57,267 | $507,741 | 1 |
| CARL WARE PHD | CENTER DIRECTOR, IIDC | 50 | $362,037 | $0 | $48,727 | $410,764 | 1 |
| JORGE MOSCAT PHD | PROGRAM DIRECTOR | 50 | $319,251 | $0 | $45,900 | $365,151 | 1 |
| DWIGHT TOWLER | PROGRAM DIRECTOR | 50 | $329,949 | $0 | $20,810 | $350,759 | 1 |
| MARGARET DUNBAR JD | SECRETARY/SR DIRECTOR IP | 50 | $172,290 | $0 | $17,562 | $189,852 | 1 |
| BRENT JACOBS | TRUSTEE | 1 | - | - | - | $0 | 2 |
| JAMES JARDON | TRUSTEE | 1 | - | - | - | $0 | 1 |
| BERNARD MACHEN | TRUSTEE | 1 | - | - | - | $0 | 1 |
| HENRY NORDOFF | TRUSTEE | 1 | - | - | - | $0 | 1 |
| DOUGLAS OBENSHAIN | TRUSTEE | 1 | - | - | - | $0 | 1 |
| PETER PREUSS | TRUSTEE | 1 | - | - | - | $0 | 5 |
| ANDREW VITERBI | TRUSTEE | 1 | - | - | - | $0 | 2 |
| ALLEN WEISS | TRUSTEE | 1 | - | - | - | $0 | 1 |
| GAYLE WILSON | TRUSTEE | 1 | - | - | - | $0 | 1 |
| GREG LUCIER | TRUSTEE/CHAIRMAN | 1 | $0 | $0 | $0 | $0 | 2 |
| DAVID DOWN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 8 |
| WILLIAM GERHART | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| RASESH THAKKAR | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| LUDER WHITLOCK | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| LORENZO BERHO | TRUSTEE | 1 | - | - | - | $0 | 1 |
| JAMES BLAIR | TRUSTEE | 1 | - | - | - | $0 | 1 |
| SHEHAN DISSANAYAKE | TRUSTEE | 1 | - | - | - | $0 | 1 |
| DANIEL EPSTEIN | TRUSTEE | 1 | - | - | - | $0 | 1 |
| WAINWRIGHT FISHBURN | TRUSTEE/PART YEAR CHAIRMAN | 1 | $0 | $0 | $0 | $0 | 2 |
| PAULINE FOSTER | TRUSTEE | 1 | - | - | - | $0 | 1 |
| PATRICK GERAGHTY | TRUSTEE | 1 | - | - | - | $0 | 1 |
| ALAN GLEICHER | TRUSTEE | 1 | - | - | - | $0 | 1 |
| JEANNE HERBERGER | TRUSTEE | 1 | - | - | - | $0 | 1 |
| JOHN C REED MD PHD | FORMER CEO | 50 | $404,882 | $0 | -$1,373,283 | -$968,401 | 2 |
2012 · 31 people listed · 9 paid, $4.7M · 1,130 employees · 22 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| JOHN C REED MD PHD | CEO | 50 | $680,710 | $0 | $400,613 | $1,081,323 | 2 |
| KRISTIINA VUORI MD PHD | PRESIDENT/INTERIM CEO | 50 | $614,402 | $0 | $336,101 | $950,503 | 3 |
| STUART LIPTON MD PHD | CENTER DIRECTOR | 50 | $448,146 | $0 | $52,739 | $500,885 | 1 |
| DANIEL KELLY MD | CNTR DIR./SCI. DIR. AT LK NONA | 50 | $446,021 | $0 | $50,001 | $496,022 | 1 |
| GARY F RAISL EDD | EVP/CAO/CFO/TREASURER | 50 | $432,812 | $0 | $48,941 | $481,753 | 1 |
| CARL WARE PHD | CENTER DIRECTOR | 50 | $347,871 | $0 | $34,808 | $382,679 | 1 |
| CYRIL DOUCET | VP, ADMIN. AT LAKE NONA | 50 | $307,670 | $0 | $35,312 | $342,982 | 1 |
| JORGE MOSCAT PHD | PROGRAM DIRECTOR | 50 | $279,856 | $0 | $45,878 | $325,734 | 1 |
| MARGARET DUNBAR JD | SECRETARY/SR DIRECTOR IP | 50 | $165,701 | $0 | $15,321 | $181,022 | 1 |
| LORENZO BERHO | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| JAMES BLAIR | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| SHEHAN DISSANAYAKE | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| DANIEL EPSTEIN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| WAIN FISHBURN | TRUSTEE/CHAIRMAN | 1 | $0 | $0 | $0 | $0 | 2 |
| PAULINE FOSTER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| PATRICK GERAGHTY | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| ALAN GLEICHER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| JEANNE HERBERGER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| BRENT JACOBS | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 2 |
| JAMES JARDON | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| ROBERT LAUER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| BERNARD MACHEN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| NICOLAS NIERENBERG | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| HENRY NORDOFF | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| DOUGLAS OBENSHAIN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| PETER PREUSS | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 5 |
| DUANE ROTH | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 5 |
| JAN TUTTLEMAN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| ANDREW VITERBI | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 2 |
| ALLEN WEISS | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| GAYLE WILSON | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
2011 · 36 people listed · 11 paid, $6.2M · 1,157 employees · 25 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| JOHN C REED MD PHD | CEO | 50 | $942,673 | $0 | $427,253 | $1,369,926 | 2 |
| KRISTIINA VUORI MD PHD | PRESIDENT | 50 | $757,003 | $0 | $345,887 | $1,102,890 | 3 |
| GARY F RAISL EDD | EVP/CAO/CFO/TREASURER | 50 | $511,225 | $0 | $50,559 | $561,784 | 1 |
| DANIEL KELLY MD | SCIENTIFIC DIRECTOR | 50 | $487,867 | $0 | $50,968 | $538,835 | 1 |
| PAUL LAIKIND PHD | SR VP CBO | 50 | $468,434 | $0 | $59,835 | $528,269 | 3 |
| STUART LIPTON MD PHD | CENTER DIRECTOR | 50 | $464,312 | $0 | $58,415 | $522,727 | 1 |
| CARL WARE PHD | CENTER DIRECTOR | 50 | $359,943 | $0 | $49,600 | $409,543 | 1 |
| EDGAR GILLENWATERS | VP EXTERNAL RELATIONS | 50 | $272,625 | $0 | $63,366 | $335,991 | 1 |
| TARIQ RANA PHD | PROGRAM DIRECTOR | 50 | $281,338 | $0 | $45,966 | $327,304 | 1 |
| JORGE MOSCAT PHD | PROFESSOR | 50 | $282,768 | $0 | $36,499 | $319,267 | 1 |
| MARGARET DUNBAR JD | SECRETARY/SR DIRECTOR IP | 50 | $172,085 | $0 | $20,302 | $192,387 | 1 |
| LORENZO BERHO | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| ARTHUR BRODY | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| SHEHAN DISSANAYAKE | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| DANIEL EPSTEIN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| WAIN FISHBURN | TRUSTEE/CHAIRMAN | 1 | $0 | $0 | $0 | $0 | 2 |
| PAULINE FOSTER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| ALAN GLEICHER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| DAVID HALE | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 11 |
| JEANNE HERBERGER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| BRENT JACOBS | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 2 |
| JAMES JARDON | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| ROBERT LAUER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| GREG LUCIER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 2 |
| ROBERT MANDELL | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| NICOLAS NIERENBERG | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| DOUGLAS OBENSHAIN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| PETER PREUSS | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 5 |
| DUANNE ROTH | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| STUART TANZ | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| JAN TUTTLEMAN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| ANDREW VITERBI | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 2 |
| BARBARA WARREN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| ALLEN WEISS | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| GAYLE WILSON | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| DIANE WINOKUR | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
2010 · 38 people listed · 10 paid, $5.7M · 1,184 employees · 28 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| JOHN C REED MD PHD | CEO | 50 | $947,875 | $0 | $528,531 | $1,476,406 | 2 |
| KRISTIINA VUORI MD PHD | PRESIDENT/DIRECTOR, CANCER CEN | 50 | $649,105 | $0 | $362,648 | $1,011,753 | 3 |
| GARY F RAISL EDD | EXECUTIVE VP/CAO/CFO/TREASURER | 50 | $486,871 | $0 | $111,509 | $598,380 | 1 |
| DANIEL KELLY MD | CENTER DIRECTOR | 50 | $493,345 | $0 | $88,948 | $582,293 | 1 |
| STUART LIPTON MD PHD | CENTER DIRECTOR | 50 | $473,197 | $0 | $74,537 | $547,734 | 1 |
| PAUL LAIKIND | SR VP, CHIEF BUSINESS OFFICER | 50 | $299,606 | $0 | $87,185 | $386,791 | 3 |
| BLAIR BLUM | SR VP, EXTERNAL RELATIONS | 50 | $319,402 | $0 | $44,392 | $363,794 | 1 |
| EDGAR GILLENWATERS | VP, EXTERNAL RELATIONS | 50 | $282,683 | $0 | $75,038 | $357,721 | 1 |
| FRED LEVINE MD PHD | TRUSTEE/CENTER DIRECTOR | 50 | $213,660 | $0 | $30,835 | $244,495 | 1 |
| CARL WARE PHD | TRUSTEE/CENTER DIRECTOR | 50 | $142,271 | $0 | $24,287 | $166,558 | 1 |
| BRIDGETTE BREN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| ARTHUR BRODY | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| MALIN BURNHAM | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 15 |
| SHEHAN DISSANYAKE | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| WAIN FISHBURN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 2 |
| JEANNIE FONTANA | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| PAULINE FOSTER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| ALAN GLEICHER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| DAVID HALE | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 11 |
| JEANNE HERBERGER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| BRENT JACOBS | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 2 |
| JIM JARDON | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| ROBERT LAUER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| SHEILA LIPINSKY | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| GREG LUCIER | TRUSTEE/CHAIRMAN | 1 | $0 | $0 | $0 | $0 | 2 |
| DOUGLAS MANCHESTER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| ROBERT MANDELL | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| NICOLAS NIERENBERG | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| DOUGLAS OBENSHAIN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| PETER PREUSS | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 5 |
| STUART TANZ | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| JAN TUTTLEMAN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| ANDREW VITERBI | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 2 |
| BARBARA BOBBI WARREN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| ALAN WEISS | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| GAYLE WILSON | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| DIANE WINOKUR | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| KEN WOOLCOTT | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
Highest-paid independent contractors
2024 · 5 contractors · $1.8M
| Name | Location | Service | Paid |
|---|---|---|---|
| DELOITTE & TOUCHE LLP | DALLAS, TX | PROFESSIONAL SERVICES | $433,527 |
| 1903 SOLUTIONS LLC | NEWPORT BEACH, CA | NETWORKING, SECURITY, IT SERVICES | $425,572 |
| BIODURO LLC | IRVINE, CA | BIOTECHNOLOGY SERVICES | $404,003 |
| UNIVERSAL PROTECTION SERVICE LP | PASADENA, CA | BUILDING SECURITY SERVICES | $286,557 |
| JAGGAER LLC | MORRISVILLE, NC | PROCUREMENT SERVICES | $233,784 |
2023 · 5 contractors · $1.3M
| Name | Location | Service | Paid |
|---|---|---|---|
| Universal Protection Service LP | Pasadena, CA | Building Security Services | $326,043 |
| Wilson Sonsini Goodrich & Rosati | Los Angeles, CA | Legal Services | $310,415 |
| Deloitte & Touche LLP | Dallas, TX | Professional Services | $269,260 |
| JAGGAER LLC | DALLAS, TX | Procurement Services | $229,200 |
| Constangy Brooks Smith & Porphete LLP | Atlanta, GA | Legal Services | $201,763 |
2022 · 5 contractors · $1.5M
| Name | Location | Service | Paid |
|---|---|---|---|
| Universal Protection Service LP | Pasadena, CA | Building security services | $374,203 |
| Deloitte & Touche LLP | Dallas, TX | Audit services | $373,337 |
| Wilson Sonsini Goodrich & Rosati | Los Angeles, CA | Legal services | $372,919 |
| JAGGAER LLC | DALLAS, TX | Digital procurement services | $224,706 |
| Divigard & Associates LLC | Northampton, MA | Consulting services | $185,088 |
2021 · 5 contractors · $2.8M
| Name | Location | Service | Paid |
|---|---|---|---|
| DPR Construction | Redwood City, CA | Construction services | $1,244,983 |
| Wilson Sonsini Goodrich & Rosati | Los Angeles, CA | Legal services | $566,374 |
| Universal Protection Service LP | Pasadena, CA | Building security services | $370,711 |
| Deloitte & Touche LLP | Dallas, TX | Audit services | $315,935 |
| Rebecca Jorgenson | Waconia, MN | Business Consulting Services | $269,740 |
2020 · 5 contractors · $1.8M
| Name | Location | Service | Paid |
|---|---|---|---|
| DPR CONSTRUCTION | REDWOOD CITY, CA | CONSTRUCTION SRVICES | $666,044 |
| WILSON SONSINI GOODRICH | LOS ANGELES, CA | LEGAL SERVICES | $377,383 |
| DELOITTE TOUCHE LLP | DALLAS, TX | AUDIT SERVICES | $303,117 |
| CARY THOMAS | CARLSBAD, CA | CONSULTING | $224,733 |
| FITCH CONTRACTING CO | LAKESIDE, CA | CONSTRUCTION SRVICES | $212,900 |
2019 · 5 contractors · $1.2M
| Name | Location | Service | Paid |
|---|---|---|---|
| DELOITTE TOUCHE LLP | SAN DIEGO, CA | AUDIT SERVICES | $384,891 |
| WILSON SONSINI GOODRICH | LOS ANGELES, CA | LEGAL SERVICES | $258,150 |
| STEALTH PARTNER GROUP | SCOTTSDALE, AZ | ADMIN SERVICES | $190,745 |
| DLA PIPER LLP | BALTIMORE, MD | LEGAL SERVICES | $180,078 |
| CLARIVATE ANALYTICS LLC | CAROL STREAM, IL | DATA CONSULTANTS | $178,713 |
2018 · 5 contractors · $1.8M
| Name | Location | Service | Paid |
|---|---|---|---|
| DLA Piper LLP | Baltimore, MD | Legal Services | $647,033 |
| Superion LLC | Chicago, IL | Software Development | $461,826 |
| DELOITTE TOUCHE LLP | SAN DIEGO, CA | AUDIT SERVICES | $287,648 |
| Wilson Sonsini Goodrich | LOS ANGELES, CA | Legal Services | $249,527 |
| Stealth Partner Group | Scottsdale, AZ | Admin Services | $203,673 |
2017 · 5 contractors · $2.1M
| Name | Location | Service | Paid |
|---|---|---|---|
| DLA PIPER US LLP | SAN DIEGO, CA | LEGAL SERVICES | $569,166 |
| Adimab LLC partnership | Lebanon, NH | Lab/Research SVCS | $456,519 |
| Allied Universal Security - Partner | Pasadena, CA | Security Services | $420,476 |
| Deloitte Touche LLP | San Diego, CA | AUDIT SERVICES | $417,295 |
| Wilson Sonsini Goodrich | Los Angeles, CA | LEGAL SERVICES | $248,000 |
2016 · 5 contractors · $1.2M
| Name | Location | Service | Paid |
|---|---|---|---|
| DLA PIPER US LLP | Baltimore, MD | Legal SERVICES | $634,757 |
| Deloitte Touche LLP | DALLAS, TX | Audit SERVICES | $191,957 |
| Pabst Patent Group LLP | Atlanta, GA | Legal SERVICES | $140,269 |
| Kenneth Widder | RANCHO SANTA FE, CA | Consulting SERVICES | $118,350 |
| Wilson Sonsini Goodrich | Los Angeles, CA | Legal SERVICES | $111,891 |
2015 · 5 contractors · $2.1M
| Name | Location | Service | Paid |
|---|---|---|---|
| DELOITTE TOUCHE LLP | SAN DIEGO, CA | AUDIT AND CONSULTING | $699,047 |
| DLA PIPER US LLP | BALTIMORE, MD | LEGAL | $496,299 |
| ARMADA ADMINISTRATORS | BALTIMORE, MD | CONSULTING-INSURANCE | $450,095 |
| STEVEN K BRAUER | SAN DIEGO, CA | CONSULTING-BUS. DEV. | $245,245 |
| BERMAN PROPERTY MANAGEMENT | KISSIMMEE, FL | PROPERTY MANAGEMENT | $227,745 |
2014 · 5 contractors · $2.6M
| Name | Location | Service | Paid |
|---|---|---|---|
| Deloitte Touche LLP | San Diego, CA | Audit and Consulting | $997,960 |
| Four Oaks Partners Consulting | Rancho Santa Fe, CA | Consulting-strat pln | $467,749 |
| Dimensional Fund Advisor | Santa Monica, CA | Consulting - inv adv | $450,000 |
| Steven K Brauer | San Diego, CA | Consulting-Bus. dev. | $445,620 |
| DLA Piper | Baltimore, MD | Legal | $277,352 |
2013 · 5 contractors · $1.3M
| Name | Location | Service | Paid |
|---|---|---|---|
| DELOITTE TOUCHE LLP | AUDIT | $295,389 | |
| STEVEN K BRAUER | Consulting Bus. Dev. | $265,335 | |
| PABST PATENT GROUP | LEGAL | $262,506 | |
| DLA PIPER | LEGAL | $252,848 | |
| BERMAN PROPERTY MANAGEMENT | JANITORIAL | $227,916 |
2012 · 5 contractors · $1.7M
| Name | Location | Service | Paid |
|---|---|---|---|
| Pabst Patent Group | ATLANTA, GA | LEGAL | $498,923 |
| DLA Piper US LLP | BALTIMORE, MD | LEGAL | $459,291 |
| Deloitte Touche | SAN DIEGO, CA | AUDIT | $297,488 |
| Berman Property Management | ORLANDO, FL | Janitorial | $215,592 |
| Jones Day | SAN DIEGO, CA | Legal | $200,927 |
2011 · 5 contractors · $2.0M
| Name | Location | Service | Paid |
|---|---|---|---|
| DLA PIPER US LLP | BALTIMORE, MD | LEGAL | $665,449 |
| PABST PATENT GROUP | ATLANTA, GA | LEGAL | $588,922 |
| JONES DAY | SAN DIEGO, CA | LEGAL | $309,882 |
| DELOITTE TOUCHE | ORLANDO, FL | AUDIT | $243,384 |
| BERMAN PROPERTY MANAGEMENT LLC | ORLANDO, FL | JANITORIAL | $237,363 |
2010 · 5 contractors · $1.9M
| Name | Location | Service | Paid |
|---|---|---|---|
| ARNALL GOLDEN GREGORY LLP | ATLANTA, GA | LEGAL | $674,221 |
| DLA PIPER US LLP | BALTIMORE, MD | LEGAL | $414,125 |
| MCDERMOTT WILL EMERY LLP | SAN DIEGO, CA | LEGAL | $349,593 |
| DELOITTE TOUCHE LLP | ORLANDO, FL | AUDIT | $318,077 |
| BERMAN PROPERTY MANAGEMENT LLP | ORLANDO, FL | JANITORIAL | $186,789 |
Who gave
Contributor names are not public for this form type.
Public charities filing Form 990 or 990-EZ report large donors on Schedule B, but the IRS withholds their names and addresses from public copies. Private foundations (990-PF) are different: their contributors are public.
Finances
Newest first. Each filing: its name on one row, its figures on the row beneath. Greyed filings are superseded by a later return for the same period and are left out everywhere else on this page.
| Revenue | Expenses | Assets | Net assets | Contributions | Program revenue | Officer pay | Employees | Volunteers |
|---|---|---|---|---|---|---|---|---|
| 2024 · Form 990 | ||||||||
| $114,401,821 | $116,107,616 | $337,965,900 | $282,330,095 | $100,911,209 | $781,895 | $1,668,689 | 611 | 14 |
| 2023 · Form 990 | ||||||||
| $123,272,481 | $111,174,592 | $326,353,986 | $268,211,594 | $107,001,067 | $669,975 | $1,465,150 | 594 | 16 |
| 2022 · Form 990 | ||||||||
| $117,219,104 | $103,397,718 | $308,605,226 | $243,533,988 | $104,423,511 | $1,012,265 | $1,054,509 | 624 | 15 |
| 2021 · Form 990 | ||||||||
| $107,303,034 | $106,781,079 | $289,830,509 | $219,630,000 | $82,047,252 | $806,855 | $2,080,338 | 645 | 15 |
| 2020 · Form 990 | ||||||||
| $124,726,984 | $108,924,075 | $337,147,969 | $260,710,870 | $111,444,313 | $853,344 | $2,404,489 | 696 | 19 |
| 2019 · Form 990 | ||||||||
| $116,730,403 | $112,647,929 | $307,274,683 | $214,124,442 | $100,963,692 | $643,286 | $1,732,086 | 779 | 19 |
| 2018 · Form 990 | ||||||||
| $122,956,459 | $186,280,858 | $338,796,799 | $215,607,420 | $108,300,329 | $799,803 | $1,240,167 | 911 | 19 |
| 2017 · Form 990 | ||||||||
| $125,326,751 | $143,519,364 | $430,760,547 | $281,665,303 | $113,630,164 | $1,300,446 | $2,696,931 | 969 | 22 |
| 2016 · Form 990 | ||||||||
| $134,174,165 | $146,845,314 | $482,051,570 | $307,188,980 | $121,777,889 | $1,413,894 | $2,391,383 | 983 | 25 |
| 2015 · Form 990 | ||||||||
| $129,105,071 | $142,368,594 | $517,058,113 | $309,195,651 | $112,687,922 | $1,984,033 | $3,584,703 | 1,015 | 22 |
| 2014 · Form 990 | ||||||||
| $255,146,810 | $151,893,967 | $427,646,063 | $332,331,211 | $244,026,040 | $906,508 | $3,011,421 | 1,000 | 20 |
| 2013 · Form 990 | ||||||||
| $153,868,003 | $142,659,251 | $339,669,216 | $231,707,004 | $146,698,221 | $1,097,834 | $2,287,173 | 1,067 | 23 |
| 2012 · Form 990 | ||||||||
| $152,710,196 | $148,976,090 | $315,253,706 | $215,038,217 | $146,497,371 | $1,077,105 | $1,841,699 | 1,130 | 22 |
| 2011 · Form 990 | ||||||||
| $162,097,035 | $158,377,766 | $316,383,458 | $207,224,221 | $156,880,684 | $774,874 | $3,820,675 | 1,157 | 25 |
| 2010 · Form 990 | ||||||||
| $162,686,057 | $161,165,052 | $321,579,555 | $206,490,814 | $160,093,433 | $0 | $3,501,465 | 1,184 | 28 |
Connected to
Organizations that list some of the same people on their returns (officers, directors, key employees on this organization’s latest return), and related organizations it lists on Schedule R.
- CONNECT FOUNDATION San Diego, CA · 3 people in common (David Brenner, David W Down, Ted Roth)
- CONNECT ASSOCIATION San Diego, CA · 3 people in common (David Brenner, David W Down, Ted Roth)
- SANFORD CONSORTIUM FOR REGENERATIVE MEDICINE La Jolla, CA · 2 people in common (David Brenner, Kristiina Vuori Md Phd)
- SAN DIEGO SPORTS ASSOCIATION San Diego, CA · 2 people in common (David W Down, Ted Roth)
- SAN DIEGO SPORTS COMMISSION San Diego, CA · 2 people in common (David W Down, Ted Roth)
- RADY CHILDRENS HOSPITAL SAN DIEGO San Diego, CA · 1 person in common (Donald Kearns)
- YMCA OF SAN DIEGO COUNTY San Diego, CA · 1 person in common (David W Down)
- RADY CHILDRENS HEALTH San Diego, CA · 1 person in common (Donald Kearns)
- RADY CHILDRENS HEALTH SERVICES SAN DIEGO San Diego, CA · 1 person in common (Donald Kearns)
- RADY CHILDRENS HOSPITAL FOUNDATION SAN DIEGO San Diego, CA · 1 person in common (Donald Kearns)
- THEATRE & ARTS FOUNDATION OF SAN DIEGO COUNTY La Jolla, CA · 1 person in common (David Brenner)
- RADY CHILDRENS HOSPITAL RESEARCH CENTER San Diego, CA · 1 person in common (Donald Kearns)
- SAN DIEGO THEATRES INC San Diego, CA · 1 person in common (David W Down)
- BIOCOM SAN DIEGO San Diego, CA · 1 person in common (David Brenner)
- SANFORD LABORATORIES FOR INNOVATIVE MEDICINES San Diego, CA · 1 person in common (Kristiina Vuori Md Phd)
- CUREBOUND INC San Diego, CA · 1 person in common (Donald Kearns)
- SAN DIEGO OPERA ASSOCIATION San Diego, CA · 1 person in common (David Brenner)
- SAN DIEGO REGIONAL CHAMBER OF COMMERCE San Diego, CA · 1 person in common (Ted Roth)
- CORPORATE DIRECTORS FORUM San Diego, CA · 1 person in common (David W Down)
Funders of this organization
114 grantors reported grants to this organization, $97,252,976 in all, tax years 2009 to 2025; the 25 largest shown (all 114). Exact: the grantor wrote this organization's EIN. Fuzzy: the grantor wrote only a name (foundations' 990-PF has no EIN field), matched to the same or a near-identical name in the same state; the name as filed is shown. From the latest return for each grantor and year, so amended returns aren't counted twice. CSV
| Grantor | Total given | Grants | Latest year's amount | Latest year | Years given | Type | Match | Grants |
|---|---|---|---|---|---|---|---|---|
| SANFORD | $9,000,000 | 3 | $1,000,000 | 2012 | 2010-2012 | Public charity | Exact | show |
| MAYO CLINIC | $6,555,594 | 12 | $179,180 | 2024 | 2013-2024 | DAF sponsor | Exact | show |
| MAYO CLINIC GROUP RETURN | $5,880,182 | 8 | $781,027 | 2024 | 2017-2024 | Public charity | Exact | show |
| AMERICAN CANCER SOCIETY INC | $5,567,613 | 7 | $300,000 | 2023 | 2010, 2017, 2019-2023 | Public charity | Exact | show |
| AMERICAN HEART ASSOCIATION INC | $5,233,634 | 11 | $63,040 | 2020 | 2010-2020 | Public charity | Exact | show |
| YALE UNIVERSITY | $4,666,530 | 8 | $277,884 | 2024 | 2009-2015, 2024 | DAF sponsor | Exact | show |
| CUREBOUND INC | $4,585,845 | 12 | $1,529,548 | 2025 | 2013-2019, 2021-2025 | Public charity | Exact | show |
| WASHINGTON UNIVERSITY | $4,094,441 | 12 | $282,037 | 2024 | 2012-2016, 2018-2024 | DAF sponsor | Exact | show |
| SANFORD | $4,000,000 | 1 | $4,000,000 | 2009 | 2009 | Public charity | Exact | show |
| UNIVERSITY OF MIAMI | $2,643,151 | 10 | $155,349 | 2021 | 2011-2014, 2016-2021 | Public charity | Exact | show |
| NORTHWESTERN UNIVERSITY | $2,569,619 | 9 | $92,806 | 2018 | 2010-2018 | DAF sponsor | Exact | show |
| DONOR ADVISED CHARITABLE GIVING | $2,188,662 | 12 | $537,000 | 2024 | 2014-2024 | DAF sponsor | Exact | show |
| SCRIPPS RESEARCH INSTITUTE | $2,057,592 | 4 | $572,762 | 2024 | 2021-2024 | Public charity | Exact | show |
| THE V FOUNDATION | $1,900,000 | 5 | $600,000 | 2024 | 2015, 2017-2018, 2021, 2024 | Public charity | Exact | show |
| DANA-FARBER CANCER INSTITUTE | $1,895,895 | 4 | $311,120 | 2012 | 2009-2012 | Public charity | Exact | show |
| MICHAEL J FOX FOUNDATION FOR PARKINSONS RESEARCH | $1,883,519 | 4 | $49,000 | 2018 | 2010, 2012, 2014, 2018 | Public charity | Exact | show |
| BILL & DINAH RUCH FAMILY FOUNDATION | $1,780,000 | 5 | $500,000 | 2025 | 2018, 2022-2025 | Private foundation | Fuzzy filed as “SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE” | show |
| BREAKTHROUGH T1D | $1,651,349 | 6 | $330,000 | 2023 | 2009, 2014-2015, 2021-2023 | Public charity | Exact | show |
| MUSCULAR DYSTROPHY ASSOCIATION | $1,625,328 | 14 | $31,500 | 2025 | 2010-2013, 2015-2019, 2022-2025 | Public charity | Exact | show |
| THE SAN DIEGO FOUNDATION | $1,454,834 | 8 | $37,500 | 2024 | 2011-2012, 2014, 2016-2018, 2023-2024 | DAF sponsor | Exact | show |
| SUSAN G KOMEN BREAST CANCER FOUNDATION | $1,432,702 | 10 | $49,994 | 2022 | 2010-2013, 2015, 2018-2020, 2022 | Public charity | Exact | show |
| American Diabetes Association Research Foundation Inc | $1,287,885 | 12 | $217,500 | 2016 | 2010, 2012-2016 | Public charity | Exact | show |
| THE MEDICAL COLLEGE OF WISCONSIN INC | $1,267,500 | 2 | $746,024 | 2024 | 2023-2024 | Public charity | Exact | show |
| BROAD INSTITUTE INC | $1,142,778 | 7 | $83,695 | 2020 | 2011-2013, 2017-2020 | Public charity | Exact | show |
| JEWISH COMMUNITY FOUNDATION OF SAN DIEGO | $1,136,205 | 15 | $18,480 | 2024 | 2010-2024 | DAF sponsor | Exact | show |
Nearby + Similar BETA
Organizations like this one: what they do and who they are linked to
Same category: NTEE code and revenue
Ranked without any AI: same NTEE code first, then the same NTEE group; then revenue within 2x, 5x or 10x; then the same state; then similar name and mission text. NTEE: the IRS’s code when it lists one, otherwise FURP’s inferred code. Same state only · More (100)
| Organization | State | NTEE | Latest revenue | Latest expenses | Top-paid title | Top pay | Why similar |
|---|---|---|---|---|---|---|---|
| STOWERS INSTITUTE FOR MEDICAL RESEARCH | MO | H92 | $102,011,512 | $104,688,153 | DIRECTOR/CHAIR DECEASED 3/27/25 | $3,206,337 | Same NTEE code H92, revenue within 2x, similar mission |
| LOVELACE BIOMEDICAL RESEARCH INSTITUTE | NM | H92 | $83,397,041 | $87,744,696 | PRESIDENT AND CHAIRMAN OF THE BOARD | $1,387,128 | Same NTEE code H92, revenue within 2x, similar mission |
| WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH | MA | H92 | $222,267,487 | $174,270,117 | DIRECTOR/PRESIDENT | $1,081,921 | Same NTEE code H92, revenue within 2x |
| FOUNDATION FOR THE NATIONAL INSTITUTE OF HEALTH INC | MD | H92 | $78,507,209 | $76,818,918 | Chief Executive Officer | $689,835 | Same NTEE code H92, revenue within 2x, similar mission |
| BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | WA | H92 | $81,277,408 | $80,732,627 | CHIEF EXECUTIVE OFFICER VMFH | $5,754,859 | Same NTEE code H92, revenue within 2x |
| OKLAHOMA MEDICAL RESEARCH FOUNDATION | OK | H92 | $136,776,829 | $126,476,987 | EVP and Chief Medical Officer | $1,016,574 | Same NTEE code H92, revenue within 2x |
| GARY AND MARY WEST HEALTH INSTITUTE | CA | H92 | $44,564,569 | $42,453,440 | CMO & EVP CLINICAL RESEARCH | $958,995 | Same NTEE code H92, revenue within 5x, same state |
| SEATTLE INSTITUTE FOR BIOMEDICAL AND CLINICAL RESEARCH | WA | H92 | $25,335,790 | $25,203,489 | DIRECTOR | $386,696 | Same NTEE code H92, revenue within 5x |
| BIOMEDICAL RESEARCH FOUNDATION OF NORTHWEST LOUISIANA | LA | H92 | $25,307,433 | $20,561,945 | CEO/PRESIDENT | $814,733 | Same NTEE code H92, revenue within 5x |
| SCRIPPS RESEARCH INSTITUTE | CA | H92 | $698,624,318 | $537,453,981 | PRESIDENT/CEO | $1,859,240 | Same NTEE code H92, revenue within 10x, same state |
| STEADMAN PHILIPPON RESEARCH INSTITUTE | CO | H92 | $14,151,760 | $16,201,121 | CHIEF SCIENTIFIC OFFICER | $661,826 | Same NTEE code H92, revenue within 10x |
| JACKSON LABORATORY | ME | H92 | $652,542,607 | $617,013,316 | PRESIDENT & CEO | $2,746,750 | Same NTEE code H92, revenue within 10x |
| WASHINGTON RESEARCH FOUNDATION | WA | H92 | $13,350,694 | $23,039,321 | PRESIDENT & CEO | $793,167 | Same NTEE code H92, revenue within 10x |
| APPLIED BIOMEDICAL SCIENCE INSTITUTE | CA | H92 | $4,539,463 | $4,281,826 | PROFESSOR | $223,011 | Same NTEE code H92, revenue differs more than 10x, same state |
| THE PANORAMA INSTITUTE OF MOLECULAR MEDICINE | CA | H92 | $65,313 | $42,054 | CHIEF EXECUTIVE OFFICER | $0 | Same NTEE code H92, revenue differs more than 10x, same state |
| BIOMEDICAL RESEARCH INSTITUTE OF SOUTHERN CALIFORNIA | CA | H92 | $141,627 | $136,871 | PRESIDENT AND CEO | $29,482 | Same NTEE code H92, revenue differs more than 10x, same state |
| FOGARTY INSTITUTE FOR INNOVATION | CA | H92 | $2,887,855 | $7,841,457 | CHIEF STRATEGY OFFICER | $377,860 | Same NTEE code H92, revenue differs more than 10x, same state |
| LIFESPAN RESEARCH INSTITUTION | CA | H92 | $1,799,122 | $6,520,518 | Chief Executive Officer | $292,427 | Same NTEE code H92, revenue differs more than 10x, same state |
| SOUTHERN CALIFORNIA INSTITUTE FOR RESEARCH AND EDUCATION | CA | H92 | $2,941,163 | $2,335,904 | Chair | $419,756 | Same NTEE code H92, revenue differs more than 10x, same state |
| GENETIC INFORMATION RESEARCH INSTITUTE | CA | H92 | $617,227 | $490,110 | Trustee | $132,779 | Same NTEE code H92, revenue differs more than 10x, same state |
| PINEHURST BIOMEDICAL FOUNDATION | CA | H92 | $8 | $60,229 | CEO | $0 | Same NTEE code H92, revenue differs more than 10x, same state |
| BIOMOLECULAR ULTRASOUND AND SONOGENETICS CONFERENCE ORG INC | CA | H92 | $123,888 | $102,655 | Secretary | $0 | Same NTEE code H92, revenue differs more than 10x, same state |
| SERVAREGMP | CA | H92 | $2,328,476 | $2,353,600 | EXECUTIVE DIRECTOR | $182,850 | Same NTEE code H92, revenue differs more than 10x, same state |
| AGOURON INSTITUTE | CA | H92 | $1,853,788 | $2,575,826 | SCIENTIST | $272,898 | Same NTEE code H92, revenue differs more than 10x, same state |
| CALIFORNIA SOCIETY FOR BIOMEDICAL RESEARCH | CA | H92 | $72,075 | $85,444 | Executive Direc | $36,360 | Same NTEE code H92, revenue differs more than 10x, same state |
Who funds organizations like this
Grantors that funded the 100 most similar organizations. Ranked by total given to them. Foundations (990-PF) and donor-advised fund sponsors only. Same matching as Funders above (by EIN, or by name for foundations).
The full list · all similar organizations
Where the money went
Every expense line on each return, biggest first: Form 990 Part IX (with its program, management and fundraising columns), 990-EZ Part I, or 990-PF Part I. Event marks lines the organization itself describes as events. “Events” in each summary adds those lines, conferences and meetings, and the direct costs of fundraising events. Unusual is not the same as improper. Many of these patterns have ordinary explanations. Check the filing.
2024 · Form 990 · $116,107,616 spent · pay $67,796,159 · grants $0 · events $948,161
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $50,537,718 | $40,304,124 | $9,301,975 | $931,619 | 43.5% | |
| Other (as described) | SCIENTIFIC COLLABORATIO | $13,371,531 | $13,371,531 | - | - | 11.5% |
| Other (as described) | RESARCH SUPPLIES & SERV | $9,114,792 | $9,114,792 | - | - | 7.9% |
| Other employee benefits | $8,798,791 | $6,810,223 | $1,848,631 | $139,937 | 7.6% | |
| Occupancy | $6,272,585 | $5,837,695 | $410,611 | $24,279 | 5.4% | |
| Depreciation and depletion | $5,621,560 | $5,235,921 | $363,715 | $21,924 | 4.8% | |
| Office expenses | $5,312,286 | $4,854,687 | $385,381 | $72,218 | 4.6% | |
| Pension plan contributions | $3,413,569 | $2,682,024 | $707,734 | $23,811 | 2.9% | |
| Payroll taxes | $3,377,392 | $2,580,106 | $727,583 | $69,703 | 2.9% | |
| Information technology | $1,910,820 | $1,328,124 | $542,389 | $40,307 | 1.6% | |
| Pay: officers, directors, trustees, key employees | $1,668,689 | $216,557 | $1,418,689 | $33,443 | 1.4% | |
| Interest | $962,864 | $896,812 | $62,297 | $3,755 | 0.8% | |
| Conferences, conventions and meetings | $948,161 | $597,449 | $334,317 | $16,395 | 0.8% | |
| Fees: management | $881,938 | $248,022 | $460,449 | $173,467 | 0.8% | |
| Fees: other services | $758,103 | $595,376 | $155,614 | $7,113 | 0.7% | |
| All other expenses | $727,777 | $201,760 | $330,504 | $195,513 | 0.6% | |
| Fees: investment management | $600,112 | - | $600,112 | - | 0.5% | |
| Fees: legal | $577,767 | $40,121 | $537,646 | - | 0.5% | |
| Other (as described) | RECRUITMENT | $368,062 | $279,904 | $86,483 | $1,675 | 0.3% |
| Travel | $290,772 | $243,322 | $43,818 | $3,632 | 0.3% | |
| Insurance | $231,487 | - | $231,487 | - | 0.2% | |
| Fees: accounting | $224,028 | - | $224,028 | - | 0.2% | |
| Other (as described) | TUITION FEES | $135,017 | $135,017 | - | - | 0.1% |
| Fees: lobbying | $1,500 | - | $1,500 | - | 0.0% | |
| Advertising and promotion | $295 | $295 | - | - | 0.0% | |
| Total | $116,107,616 | 100% |
2023 · Form 990 · $111,174,592 spent · pay $63,300,127 · grants $0 · events $1,459,011
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $47,639,883 | $38,317,433 | $8,456,820 | $865,630 | 42.9% | |
| Other (as described) | SCIENTIFIC COLLABORATIONS | $11,008,033 | $11,008,033 | $0 | $0 | 9.9% |
| Other (as described) | RESEARCH SUPPLIES & SVCS | $9,888,051 | $9,887,929 | $3 | $119 | 8.9% |
| Other employee benefits | $7,624,582 | $5,886,415 | $1,376,517 | $361,650 | 6.9% | |
| Occupancy | $6,575,946 | $6,149,262 | $401,887 | $24,797 | 5.9% | |
| Office expenses | $5,634,672 | $5,076,466 | $540,521 | $17,685 | 5.1% | |
| Depreciation and depletion | $5,369,141 | $5,023,905 | $324,833 | $20,403 | 4.8% | |
| Payroll taxes | $3,132,386 | $2,412,870 | $653,549 | $65,967 | 2.8% | |
| Pension plan contributions | $3,096,876 | $2,417,032 | $625,235 | $54,609 | 2.8% | |
| Information technology | $1,689,633 | $1,215,046 | $441,169 | $33,418 | 1.5% | |
| Pay: officers, directors, trustees, key employees | $1,465,150 | $32,500 | $1,286,400 | $146,250 | 1.3% | |
| Interest | $1,151,762 | $1,077,703 | $69,682 | $4,377 | 1.0% | |
| Conferences, conventions and meetings | $1,004,212 | $662,268 | $338,044 | $3,900 | 0.9% | |
| Fees: legal | $928,176 | $62,346 | $855,330 | $10,500 | 0.8% | |
| All other expenses | $922,897 | $63,824 | $804,638 | $54,435 | 0.8% | |
| Fees: other services | $861,908 | $569,281 | $243,903 | $48,724 | 0.8% | |
| Fees: management | $809,508 | $273,878 | $453,260 | $82,370 | 0.7% | |
| Fees: investment management | $679,787 | $0 | $679,787 | $0 | 0.6% | |
| Fees: accounting | $421,627 | $0 | $421,627 | $0 | 0.4% | |
| Travel | $361,891 | $328,382 | $30,749 | $2,760 | 0.3% | |
| Pay: disqualified persons | $341,250 | $0 | $341,250 | $0 | 0.3% | |
| Insurance | $230,910 | $0 | $230,910 | $0 | 0.2% | |
| Other (as described) | RECRUITMENT | $220,928 | $151,902 | $62,615 | $6,411 | 0.2% |
| Other (as described) | TUITION FEES | $112,908 | $112,908 | $0 | $0 | 0.1% |
| Fees: lobbying | $1,500 | $0 | $1,500 | $0 | 0.0% | |
| Advertising and promotion | $975 | $0 | $975 | $0 | 0.0% | |
| Fundraising events Event | direct expenses; gross income $422,000 | $454,799 | reported apart | |||
| Total | $111,174,592 | 100% |
2022 · Form 990 · $103,397,718 spent · pay $58,193,349 · grants $0 · events $1,277,926
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $44,095,826 | $34,324,157 | $8,614,372 | $1,157,297 | 42.6% | |
| Other (as described) | SCIENTIFIC COLLABORATIONS | $10,383,161 | $10,383,161 | $0 | $0 | 10.0% |
| Other (as described) | RESEARCH SUPPLIES & SVCS | $9,633,741 | $9,631,881 | $1,860 | - | 9.3% |
| Other employee benefits | $7,401,327 | $5,628,997 | $1,597,200 | $175,130 | 7.2% | |
| Occupancy | $6,742,030 | $6,300,154 | $415,040 | $26,836 | 6.5% | |
| Office expenses | $5,365,932 | $4,919,280 | $385,735 | $60,917 | 5.2% | |
| Depreciation and depletion | $5,180,844 | $4,846,162 | $313,959 | $20,723 | 5.0% | |
| Payroll taxes | $2,833,481 | $2,134,035 | $634,473 | $64,973 | 2.7% | |
| Pension plan contributions | $2,808,206 | $2,186,957 | $574,808 | $46,441 | 2.7% | |
| Information technology | $1,494,399 | $1,053,828 | $407,175 | $33,396 | 1.4% | |
| Interest | $1,319,092 | $1,233,879 | $79,937 | $5,276 | 1.3% | |
| Conferences, conventions and meetings | $1,277,926 | $665,430 | $605,750 | $6,746 | 1.2% | |
| Pay: officers, directors, trustees, key employees | $1,054,509 | $0 | $937,603 | $116,906 | 1.0% | |
| Fees: other services | $904,348 | $721,866 | $149,758 | $32,724 | 0.9% | |
| Fees: investment management | $553,900 | $0 | $553,900 | $0 | 0.5% | |
| Fees: management | $531,870 | $174,399 | $300,165 | $57,306 | 0.5% | |
| Fees: accounting | $440,906 | $0 | $440,906 | $0 | 0.4% | |
| All other expenses | $389,957 | $147,093 | $199,843 | $43,021 | 0.4% | |
| Travel | $275,140 | $243,583 | $28,472 | $3,085 | 0.3% | |
| Other (as described) | RECRUITMENT | $262,717 | $174,340 | $49,521 | $38,856 | 0.3% |
| Insurance | $220,382 | $0 | $220,382 | $0 | 0.2% | |
| Other (as described) | TUITION FEES | $126,457 | $126,457 | $0 | $0 | 0.1% |
| Fees: legal | $100,052 | $58,449 | $41,603 | $0 | 0.1% | |
| Fees: lobbying | $1,500 | $0 | $1,500 | $0 | 0.0% | |
| Advertising and promotion | $15 | $0 | $15 | $0 | 0.0% | |
| Total | $103,397,718 | 100% |
2021 · Form 990 · $106,781,079 spent · pay $59,973,447 · grants $0 · events $552,326
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $40,485,652 | $31,224,439 | $8,513,846 | $747,367 | 37.9% | |
| Other employee benefits | $11,937,448 | $5,227,156 | $6,619,219 | $91,073 | 11.2% | |
| Other (as described) | RESEARCH SUPPLIES & SVCS | $9,820,069 | $9,820,069 | $0 | $0 | 9.2% |
| Other (as described) | SCIENTIFIC COLLABORATIONS | $8,751,368 | $8,751,368 | $0 | $0 | 8.2% |
| Occupancy | $7,902,738 | $7,415,941 | $481,228 | $5,569 | 7.4% | |
| Depreciation and depletion | $6,870,296 | $6,451,208 | $414,279 | $4,809 | 6.4% | |
| Office expenses | $5,193,586 | $4,771,381 | $386,349 | $35,856 | 4.9% | |
| Payroll taxes | $2,780,289 | $1,999,330 | $727,325 | $53,634 | 2.6% | |
| Pension plan contributions | $2,689,720 | $2,115,179 | $564,075 | $10,466 | 2.5% | |
| Pay: officers, directors, trustees, key employees | $2,080,338 | $134,516 | $1,945,822 | $0 | 1.9% | |
| Interest | $1,451,168 | $1,362,647 | $87,505 | $1,016 | 1.4% | |
| Information technology | $1,392,845 | $937,330 | $409,163 | $46,352 | 1.3% | |
| Fees: management | $1,392,039 | $209,911 | $1,091,797 | $90,331 | 1.3% | |
| Fees: other services | $763,880 | $581,804 | $129,388 | $52,688 | 0.7% | |
| Fees: investment management | $663,576 | $0 | $663,576 | $0 | 0.6% | |
| Conferences, conventions and meetings | $552,326 | $327,575 | $200,566 | $24,185 | 0.5% | |
| Other (as described) | RECRUITMENT | $525,227 | $201,824 | $307,176 | $16,227 | 0.5% |
| Fees: accounting | $412,305 | $0 | $412,305 | $0 | 0.4% | |
| Fees: legal | $389,089 | $72,100 | $316,989 | $0 | 0.4% | |
| Insurance | $221,813 | $0 | $221,813 | $0 | 0.2% | |
| Travel | $192,838 | $152,811 | $39,851 | $176 | 0.2% | |
| Other (as described) | TUITION FEES | $155,790 | $155,790 | $0 | $0 | 0.1% |
| All other expenses | $154,659 | $63,027 | $37,985 | $53,647 | 0.1% | |
| Advertising and promotion | $2,020 | $2,000 | $20 | $0 | 0.0% | |
| Total | $106,781,079 | 100% |
2020 · Form 990 · $108,924,075 spent · pay $58,840,604 · grants $0 · events $178,194
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $43,157,602 | $33,177,744 | $9,166,487 | $813,371 | 39.6% | |
| Other (as described) | RESEARCH SUPPLIES & SVCS | $10,801,063 | $10,801,063 | - | - | 9.9% |
| Occupancy | $9,447,676 | $8,388,325 | $984,079 | $75,272 | 8.7% | |
| Other (as described) | SCIENTIFIC COLLABORATIONS | $8,986,112 | $8,986,112 | - | - | 8.2% |
| Other employee benefits | $7,433,905 | $5,316,296 | $2,017,852 | $99,757 | 6.8% | |
| Depreciation and depletion | $6,564,887 | $5,832,246 | $680,122 | $52,519 | 6.0% | |
| Office expenses | $5,357,657 | $4,928,905 | $406,900 | $21,852 | 4.9% | |
| Pension plan contributions | $3,021,491 | $2,328,480 | $650,673 | $42,338 | 2.8% | |
| Payroll taxes | $2,823,117 | $2,103,853 | $669,660 | $49,604 | 2.6% | |
| Pay: officers, directors, trustees, key employees | $2,404,489 | $5,793 | $2,398,696 | - | 2.2% | |
| Fees: management | $1,910,166 | $366,818 | $1,476,011 | $67,337 | 1.8% | |
| Interest | $1,616,248 | $1,435,875 | $167,443 | $12,930 | 1.5% | |
| Fees: other services | $1,334,440 | $1,120,804 | $187,550 | $26,086 | 1.2% | |
| Information technology | $1,282,857 | $900,588 | $351,493 | $30,776 | 1.2% | |
| Other (as described) | RECRUITMENT | $805,509 | $274,008 | $421,147 | $110,354 | 0.7% |
| Fees: investment management | $654,971 | - | $654,971 | - | 0.6% | |
| Fees: accounting | $372,221 | - | $372,221 | - | 0.3% | |
| Fees: legal | $276,367 | $49,245 | $227,122 | - | 0.3% | |
| Insurance | $199,066 | - | $199,066 | - | 0.2% | |
| Conferences, conventions and meetings | $178,194 | $133,266 | $36,560 | $8,368 | 0.2% | |
| Other (as described) | TUITION FEES | $130,180 | $130,180 | - | - | 0.1% |
| All other expenses | $129,222 | $31,063 | $61,472 | $36,687 | 0.1% | |
| Travel | $28,152 | $25,981 | $2,164 | $7 | 0.0% | |
| Advertising and promotion | $8,483 | $500 | $7,983 | - | 0.0% | |
| Total | $108,924,075 | 100% |
2019 · Form 990 · $112,647,929 spent · pay $62,755,446 · grants $0 · events $1,088,270
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $47,298,550 | $37,613,090 | $8,872,115 | $813,345 | 42.0% | |
| Occupancy | $10,985,009 | $10,013,170 | $903,696 | $68,143 | 9.8% | |
| Other (as described) | RESEARCH SUPPLIES & SVCS | $9,195,443 | $9,195,443 | $0 | $0 | 8.2% |
| Other (as described) | Scientific collaborations | $8,532,168 | $8,532,168 | $0 | $0 | 7.6% |
| Other employee benefits | $7,516,566 | $5,939,878 | $1,480,539 | $96,149 | 6.7% | |
| Depreciation and depletion | $7,050,756 | $6,430,289 | $576,752 | $43,715 | 6.3% | |
| Office expenses | $5,649,705 | $4,967,362 | $631,083 | $51,260 | 5.0% | |
| Pension plan contributions | $3,233,587 | $2,496,251 | $681,134 | $56,202 | 2.9% | |
| Payroll taxes | $2,974,657 | $2,241,787 | $680,054 | $52,816 | 2.6% | |
| Interest | $1,778,605 | $1,622,088 | $145,490 | $11,027 | 1.6% | |
| Pay: officers, directors, trustees, key employees | $1,732,086 | $154,502 | $1,577,584 | $0 | 1.5% | |
| Information technology | $1,250,113 | $920,349 | $299,493 | $30,271 | 1.1% | |
| Fees: management | $1,193,907 | $152,805 | $947,216 | $93,886 | 1.1% | |
| Conferences, conventions and meetings | $928,370 | $672,391 | $247,820 | $8,159 | 0.8% | |
| Fees: other services | $904,054 | $634,330 | $264,443 | $5,281 | 0.8% | |
| Fees: investment management | $628,171 | $0 | $628,171 | $0 | 0.6% | |
| Fees: legal | $481,077 | $38,648 | $442,429 | $0 | 0.4% | |
| Fees: accounting | $348,063 | $0 | $348,063 | $0 | 0.3% | |
| Travel | $298,833 | $261,466 | $35,489 | $1,878 | 0.3% | |
| All other expenses | $294,657 | $96,234 | $92,750 | $105,673 | 0.3% | |
| Insurance | $184,870 | $0 | $184,870 | $0 | 0.2% | |
| Other (as described) | TUITION FEES | $116,358 | $116,358 | $0 | $0 | 0.1% |
| Other (as described) | BAD DEBT | $58,322 | $0 | $58,322 | $0 | 0.1% |
| Advertising and promotion | $12,502 | $0 | $12,502 | $0 | 0.0% | |
| Fees: lobbying | $1,500 | $0 | $1,500 | $0 | 0.0% | |
| Fundraising events Event | direct expenses; gross income $27,000 | $159,900 | reported apart | |||
| Total | $112,647,929 | 100% |
2018 · Form 990 · $186,280,858 spent · pay $65,811,734 · grants $0 · events $1,400,810
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other (as described) | CONTRIBUTED ASSETS | $65,411,144 | $0 | $65,411,144 | $0 | 35.1% |
| Other salaries and wages | $49,409,343 | $39,978,741 | $8,753,432 | $677,170 | 26.5% | |
| Occupancy | $12,201,330 | $10,856,400 | $1,273,424 | $71,506 | 6.5% | |
| Other (as described) | RESEARCH SUPPLIES & SVCS | $10,410,668 | $10,410,668 | $0 | $0 | 5.6% |
| Depreciation and depletion | $8,968,041 | $8,121,441 | $794,225 | $52,375 | 4.8% | |
| Other (as described) | SCIENTIFIC COLLABORATIONS | $8,089,399 | $8,089,399 | $0 | $0 | 4.3% |
| Other employee benefits | $8,054,800 | $6,589,802 | $1,401,993 | $63,005 | 4.3% | |
| Office expenses | $6,366,860 | $5,663,217 | $654,581 | $49,062 | 3.4% | |
| Pension plan contributions | $3,325,036 | $2,636,505 | $632,128 | $56,403 | 1.8% | |
| Payroll taxes | $3,001,930 | $2,303,943 | $655,231 | $42,756 | 1.6% | |
| Interest | $1,919,481 | $1,747,687 | $158,933 | $12,861 | 1.0% | |
| Information technology | $1,459,944 | $1,107,654 | $314,321 | $37,969 | 0.8% | |
| Pay: officers, directors, trustees, key employees | $1,240,167 | $154,502 | $1,085,665 | $0 | 0.7% | |
| Fees: management | $1,084,184 | $417,876 | $610,208 | $56,100 | 0.6% | |
| Conferences, conventions and meetings | $1,046,410 | $805,009 | $202,674 | $38,727 | 0.6% | |
| Fees: other services | $818,904 | $634,526 | $172,704 | $11,674 | 0.4% | |
| Pay: disqualified persons | $780,458 | $0 | $780,458 | $0 | 0.4% | |
| Fees: investment management | $697,100 | $0 | $697,100 | $0 | 0.4% | |
| Fees: legal | $643,181 | $54,570 | $588,611 | $0 | 0.3% | |
| Travel | $425,568 | $366,755 | $51,894 | $6,919 | 0.2% | |
| Fees: accounting | $375,420 | $0 | $375,420 | $0 | 0.2% | |
| All other expenses | $304,031 | $186,619 | $40,373 | $77,039 | 0.2% | |
| Other (as described) | Bad Debt | $222,285 | $0 | $222,285 | $0 | 0.1% |
| Advertising and promotion | $23,974 | $0 | $108 | $23,866 | 0.0% | |
| Fees: lobbying | $1,200 | $0 | $1,200 | $0 | 0.0% | |
| Fundraising events Event | direct expenses; gross income $59,487 | $354,400 | reported apart | |||
| Total | $186,280,858 | 100% |
2017 · Form 990 · $143,519,364 spent · pay $76,269,756 · grants $0 · events $1,481,742
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $57,562,490 | $46,896,620 | $9,887,060 | $778,810 | 40.1% | |
| Depreciation and depletion | $13,919,772 | $12,560,655 | $1,294,091 | $65,026 | 9.7% | |
| Occupancy | $13,737,146 | $12,162,746 | $1,488,145 | $86,255 | 9.6% | |
| Other (as described) | RESEARCH SUPPLIES & SERVICES | $13,215,854 | $13,215,854 | $0 | $0 | 9.2% |
| Other employee benefits | $8,779,133 | $7,344,977 | $1,359,065 | $75,091 | 6.1% | |
| Office expenses | $7,794,564 | $6,985,035 | $762,007 | $47,522 | 5.4% | |
| Other (as described) | SCIENTIFIC COLLABORATIONS | $7,157,418 | $7,157,418 | $0 | $0 | 5.0% |
| Pension plan contributions | $3,771,796 | $3,082,013 | $638,088 | $51,695 | 2.6% | |
| Payroll taxes | $3,459,406 | $2,712,977 | $693,443 | $52,986 | 2.4% | |
| Pay: officers, directors, trustees, key employees | $2,696,931 | $158,377 | $2,538,554 | - | 1.9% | |
| Interest | $2,044,147 | $1,853,837 | $173,344 | $16,966 | 1.4% | |
| Fees: management | $1,721,171 | $867,152 | $845,514 | $8,505 | 1.2% | |
| Information technology | $1,437,250 | $1,066,233 | $340,494 | $30,523 | 1.0% | |
| Fees: other services | $1,274,282 | $561,743 | $701,480 | $11,059 | 0.9% | |
| Conferences, conventions and meetings | $1,202,241 | $949,079 | $224,784 | $28,378 | 0.8% | |
| Fees: legal | $1,147,792 | $38,754 | $1,109,038 | $0 | 0.8% | |
| Travel | $720,200 | $639,575 | $72,121 | $8,504 | 0.5% | |
| Other (as described) | BAD DEBT | $576,628 | $0 | $576,628 | $0 | 0.4% |
| All other expenses | $437,485 | $242,542 | $106,103 | $88,840 | 0.3% | |
| Other (as described) | CONTRIBUTED ASSETS | $387,651 | $0 | $387,651 | $0 | 0.3% |
| Fees: accounting | $384,853 | $0 | $384,853 | $0 | 0.3% | |
| Advertising and promotion | $51,701 | $2,625 | $0 | $49,076 | 0.0% | |
| Insurance | $22,857 | $0 | $22,857 | $0 | 0.0% | |
| Fees: investment management | $15,536 | $0 | $15,536 | $0 | 0.0% | |
| Fees: lobbying | $1,060 | $0 | $1,060 | $0 | 0.0% | |
| Fundraising events Event | direct expenses; gross income $52,500 | $279,501 | reported apart | |||
| Total | $143,519,364 | 100% |
2016 · Form 990 · $146,845,314 spent · pay $79,341,143 · grants $0 · events $1,473,334
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $60,650,213 | $48,931,572 | $10,917,314 | $801,327 | 41.3% | |
| Other (as described) | RESEARCH SUPPLIES & SERV. | $14,706,631 | $14,706,631 | $0 | $0 | 10.0% |
| Occupancy | $13,450,575 | $12,058,762 | $1,307,241 | $84,572 | 9.2% | |
| Depreciation and depletion | $13,127,059 | $11,843,510 | $1,225,692 | $57,857 | 8.9% | |
| Office expenses | $8,813,036 | $7,869,629 | $845,653 | $97,754 | 6.0% | |
| Other employee benefits | $8,692,549 | $7,145,436 | $1,442,886 | $104,227 | 5.9% | |
| Other (as described) | Scientific collaborations | $4,567,950 | $4,567,950 | $0 | $0 | 3.1% |
| Pension plan contributions | $3,977,082 | $3,252,754 | $675,228 | $49,100 | 2.7% | |
| Payroll taxes | $3,629,916 | $2,821,696 | $751,430 | $56,790 | 2.5% | |
| Pay: officers, directors, trustees, key employees | $2,391,383 | $243,210 | $2,148,173 | $0 | 1.6% | |
| Interest | $2,162,878 | $1,961,514 | $183,412 | $17,952 | 1.5% | |
| Other (as described) | Bad Debt | $1,891,263 | $0 | $1,891,263 | $0 | 1.3% |
| Fees: management | $1,755,607 | $940,071 | $743,178 | $72,358 | 1.2% | |
| Fees: other services | $1,508,777 | $710,539 | $783,576 | $14,662 | 1.0% | |
| Information technology | $1,401,290 | $1,102,617 | $263,472 | $35,201 | 1.0% | |
| Conferences, conventions and meetings | $1,193,091 | $877,587 | $284,224 | $31,280 | 0.8% | |
| Fees: legal | $1,069,842 | $52,701 | $1,017,141 | $0 | 0.7% | |
| Travel | $554,902 | $457,532 | $93,631 | $3,739 | 0.4% | |
| Fees: accounting | $400,371 | $0 | $400,371 | $0 | 0.3% | |
| All other expenses | $364,979 | $113,153 | $150,221 | $101,605 | 0.2% | |
| Other (as described) | Recruitment | $250,018 | $189,837 | $60,065 | $116 | 0.2% |
| Insurance | $146,793 | - | $146,793 | $0 | 0.1% | |
| Fees: lobbying | $67,275 | $0 | $67,275 | $0 | 0.0% | |
| Advertising and promotion | $56,734 | $3,155 | $7,777 | $45,802 | 0.0% | |
| Fees: investment management | $15,100 | $0 | $15,100 | $0 | 0.0% | |
| Fundraising events Event | direct expenses; gross income $57,000 | $280,243 | reported apart | |||
| Total | $146,845,314 | 100% |
2015 · Form 990 · $142,368,594 spent · pay $77,528,317 · grants $0 · events $1,415,311
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $58,397,347 | $47,973,116 | $9,374,837 | $1,049,394 | 41.0% | |
| Occupancy | $13,666,798 | $12,214,014 | $1,342,832 | $109,952 | 9.6% | |
| Other (as described) | RESEARCH SUPPLIES & SERV. | $12,961,698 | $12,961,698 | - | - | 9.1% |
| Depreciation and depletion | $12,710,838 | $11,389,200 | $1,232,173 | $89,465 | 8.9% | |
| Office expenses | $8,212,293 | $7,475,191 | $650,838 | $86,264 | 5.8% | |
| Other employee benefits | $8,135,849 | $6,812,027 | $1,204,963 | $118,859 | 5.7% | |
| Interest | $5,177,017 | $4,366,294 | $770,762 | $39,961 | 3.6% | |
| Pension plan contributions | $3,873,972 | $3,217,835 | $606,141 | $49,996 | 2.7% | |
| Other (as described) | SCIENTIFIC COLLABORATIONS | $3,863,964 | $3,863,964 | $0 | $0 | 2.7% |
| Pay: officers, directors, trustees, key employees | $3,584,703 | $237,062 | $3,347,641 | $0 | 2.5% | |
| Payroll taxes | $3,536,446 | $2,748,283 | $715,861 | $72,302 | 2.5% | |
| Fees: management | $1,534,442 | $844,795 | $683,773 | $5,874 | 1.1% | |
| Information technology | $1,297,036 | $960,885 | $303,392 | $32,759 | 0.9% | |
| Conferences, conventions and meetings | $1,225,902 | $943,532 | $260,859 | $21,511 | 0.9% | |
| Fees: legal | $1,086,661 | $47,704 | $1,038,815 | $142 | 0.8% | |
| Fees: other services | $952,032 | $518,959 | $420,724 | $12,349 | 0.7% | |
| Travel | $565,634 | $469,924 | $87,540 | $8,170 | 0.4% | |
| Other (as described) | RECRUITMENT | $544,344 | $250,798 | $279,054 | $14,492 | 0.4% |
| Fees: accounting | $366,170 | $0 | $366,170 | $0 | 0.3% | |
| All other expenses | $222,796 | $99,020 | $24,086 | $99,690 | 0.2% | |
| Fees: lobbying | $195,400 | $0 | $195,400 | $0 | 0.1% | |
| Insurance | $101,636 | $0 | $101,636 | $0 | 0.1% | |
| Other (as described) | BAD DEBT | $95,594 | - | $95,594 | - | 0.1% |
| Advertising and promotion | $40,776 | $10,985 | $9,559 | $20,232 | 0.0% | |
| Fees: investment management | $19,246 | $0 | $19,246 | $0 | 0.0% | |
| Fundraising events Event | direct expenses; gross income $45,150 | $189,409 | reported apart | |||
| Total | $142,368,594 | 100% |
2014 · Form 990 · $151,893,967 spent · pay $77,062,612 · grants $0 · events $1,512,166
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $56,763,016 | $48,603,328 | $7,604,718 | $554,970 | 37.4% | |
| Depreciation and depletion | $14,811,018 | $13,405,174 | $1,311,093 | $94,751 | 9.8% | |
| Occupancy | $14,038,551 | $12,543,861 | $1,382,227 | $112,463 | 9.2% | |
| Other (as described) | RESEARCH SUPPLIES & SERV. | $13,598,215 | $13,598,215 | $0 | $0 | 9.0% |
| Other employee benefits | $9,467,783 | $7,946,423 | $1,401,109 | $120,251 | 6.2% | |
| Office expenses | $8,057,300 | $7,266,024 | $641,667 | $149,609 | 5.3% | |
| Other (as described) | SCIENTIFIC COLLABORATIONS | $7,178,024 | $7,178,024 | $0 | $0 | 4.7% |
| All other expenses | $4,481,894 | $90,057 | $4,187,125 | $204,712 | 3.0% | |
| Pension plan contributions | $4,119,003 | $3,260,631 | $808,358 | $50,014 | 2.7% | |
| Payroll taxes | $3,541,239 | $2,871,698 | $621,541 | $48,000 | 2.3% | |
| Interest | $3,329,574 | $3,025,919 | $276,020 | $27,635 | 2.2% | |
| Pay: officers, directors, trustees, key employees | $3,011,421 | $242,400 | $2,769,021 | $0 | 2.0% | |
| Fees: management | $2,872,813 | $1,010,906 | $1,719,531 | $142,376 | 1.9% | |
| Information technology | $1,347,846 | $1,073,777 | $248,905 | $25,164 | 0.9% | |
| Conferences, conventions and meetings | $1,273,430 | $920,057 | $325,128 | $28,245 | 0.8% | |
| Fees: other services | $1,038,092 | $702,987 | $323,512 | $11,593 | 0.7% | |
| Travel | $678,776 | $531,555 | $135,554 | $11,667 | 0.4% | |
| Fees: legal | $578,459 | $52,191 | $526,268 | $0 | 0.4% | |
| Other (as described) | RECRUITMENT | $522,629 | $256,755 | $249,619 | $16,255 | 0.3% |
| Fees: accounting | $352,559 | $0 | $352,559 | $0 | 0.2% | |
| Fees: professional fundraisers | $261,304 | - | - | $261,304 | 0.2% | |
| Fees: lobbying | $169,315 | $0 | $169,315 | $0 | 0.1% | |
| Pay: disqualified persons | $160,150 | $0 | $16,015 | $144,135 | 0.1% | |
| Insurance | $86,495 | $0 | $86,495 | $0 | 0.1% | |
| Other (as described) | UBI TAXES | $73,866 | $0 | $73,866 | $0 | 0.0% |
| Advertising and promotion | $61,739 | $0 | $16,701 | $45,038 | 0.0% | |
| Fees: investment management | $19,456 | $0 | $19,456 | $0 | 0.0% | |
| Fundraising events Event | direct expenses; gross income $33,000 | $238,736 | reported apart | |||
| Total | $151,893,967 | 100% |
2013 · Form 990 · $142,659,251 spent · pay $74,256,935 · grants $0 · events $1,569,607
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $56,135,155 | $47,836,192 | $7,269,248 | $1,029,715 | 39.3% | |
| Depreciation and depletion | $17,374,712 | $15,445,839 | $1,809,715 | $119,158 | 12.2% | |
| Occupancy | $13,688,682 | $12,218,346 | $1,361,494 | $108,842 | 9.6% | |
| Other (as described) | Research supplies & serv | $10,690,315 | $10,690,315 | $0 | $0 | 7.5% |
| Office expenses | $9,173,659 | $8,489,036 | $594,648 | $89,975 | 6.4% | |
| Other employee benefits | $8,426,086 | $7,240,288 | $1,032,736 | $153,062 | 5.9% | |
| Other (as described) | Scientific collaborations | $5,180,540 | $5,180,540 | $0 | $0 | 3.6% |
| Pension plan contributions | $3,780,907 | $3,159,424 | $552,064 | $69,419 | 2.7% | |
| Interest | $3,439,937 | $3,126,514 | $285,162 | $28,261 | 2.4% | |
| Payroll taxes | $3,433,164 | $2,799,450 | $556,390 | $77,324 | 2.4% | |
| Pay: officers, directors, trustees, key employees | $2,287,173 | $537,746 | $1,749,427 | $0 | 1.6% | |
| Fees: management | $2,203,331 | $839,961 | $1,354,785 | $8,585 | 1.5% | |
| Information technology | $1,359,158 | $1,068,848 | $260,042 | $30,268 | 1.0% | |
| Conferences, conventions and meetings | $1,312,067 | $975,572 | $311,403 | $25,092 | 0.9% | |
| Fees: other services | $989,957 | $736,041 | $245,711 | $8,205 | 0.7% | |
| Travel | $679,657 | $576,023 | $87,670 | $15,964 | 0.5% | |
| Fees: legal | $584,109 | $52,576 | $523,346 | $8,187 | 0.4% | |
| Other (as described) | Miscellaneous | $490,678 | $153,296 | $203,880 | $133,502 | 0.3% |
| Other (as described) | Recruitment | $448,679 | $157,550 | $290,666 | $463 | 0.3% |
| Fees: accounting | $399,991 | $0 | $399,991 | $0 | 0.3% | |
| Pay: disqualified persons | $194,450 | $0 | $19,445 | $175,005 | 0.1% | |
| Fees: lobbying | $141,533 | $0 | $141,533 | $0 | 0.1% | |
| Insurance | $82,695 | $0 | $82,695 | $0 | 0.1% | |
| Fees: professional fundraisers | $80,888 | - | - | $80,888 | 0.1% | |
| Advertising and promotion | $65,538 | $10,843 | $3,509 | $51,186 | 0.0% | |
| Fees: investment management | $16,190 | $0 | $16,190 | $0 | 0.0% | |
| Fundraising events Event | direct expenses; gross income $43,800 | $257,540 | reported apart | |||
| Total | $142,659,251 | 100% |
2012 · Form 990 · $148,976,090 spent · pay $79,343,211 · grants $0 · events $1,558,764
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $60,510,538 | $50,837,956 | $8,237,101 | $1,435,481 | 40.6% | |
| Depreciation and depletion | $19,065,947 | $16,654,008 | $2,263,256 | $148,683 | 12.8% | |
| Occupancy | $13,284,137 | $11,802,321 | $1,364,933 | $116,883 | 8.9% | |
| Other (as described) | RESEARCH SUPPLIES & EXPENSES | $10,479,721 | $10,479,721 | - | - | 7.0% |
| Office expenses | $9,308,668 | $8,628,160 | $589,168 | $91,340 | 6.2% | |
| Other employee benefits | $8,906,179 | $7,220,690 | $1,521,434 | $164,055 | 6.0% | |
| Other (as described) | SCIENTIFIC COLLABORATIONS | $6,616,691 | $6,616,691 | - | - | 4.4% |
| Pension plan contributions | $4,167,689 | $3,388,695 | $689,405 | $89,589 | 2.8% | |
| Payroll taxes | $3,725,968 | $3,053,466 | $583,449 | $89,053 | 2.5% | |
| Interest | $3,710,284 | $3,367,833 | $307,574 | $34,877 | 2.5% | |
| Pay: officers, directors, trustees, key employees | $1,841,699 | $2,115,745 | -$274,046 | - | 1.2% | |
| Fees: management | $1,464,931 | $1,119,204 | $345,480 | $247 | 1.0% | |
| Information technology | $1,315,093 | $1,009,512 | $281,248 | $24,333 | 0.9% | |
| Conferences, conventions and meetings | $1,194,284 | $844,290 | $319,367 | $30,627 | 0.8% | |
| Travel | $785,657 | $678,326 | $85,927 | $21,404 | 0.5% | |
| Fees: other services | $756,085 | $575,134 | $164,463 | $16,488 | 0.5% | |
| Other (as described) | RECRUITMENT | $385,513 | $330,049 | $30,955 | $24,509 | 0.3% |
| Fees: legal | $379,952 | $44,781 | $335,171 | - | 0.3% | |
| Fees: accounting | $305,901 | - | $305,901 | - | 0.2% | |
| Other (as described) | MISCELLANEOUS | $272,826 | $119,528 | $48,879 | $104,419 | 0.2% |
| Pay: disqualified persons | $191,138 | $191,138 | - | - | 0.1% | |
| Fees: lobbying | $123,133 | $245 | $122,888 | - | 0.1% | |
| Insurance | $85,144 | - | $85,144 | - | 0.1% | |
| Advertising and promotion | $53,399 | $220 | $15,239 | $37,940 | 0.0% | |
| Fees: professional fundraisers | $33,225 | - | - | $33,225 | 0.0% | |
| Fees: investment management | $12,288 | - | $12,288 | - | 0.0% | |
| Fundraising events Event | direct expenses; gross income - | $364,480 | reported apart | |||
| Total | $148,976,090 | 100% |
2011 · Form 990 · $158,377,766 spent · pay $82,248,203 · grants $0 · events $1,994,760
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $61,993,413 | $51,424,649 | $8,872,346 | $1,696,418 | 39.1% | |
| Depreciation and depletion | $19,986,867 | $17,405,538 | $2,396,889 | $184,440 | 12.6% | |
| Occupancy | $13,817,632 | $12,302,843 | $1,383,193 | $131,596 | 8.7% | |
| Other (as described) | Research supplies & services | $12,684,932 | $12,684,932 | - | - | 8.0% |
| Office expenses | $9,820,758 | $9,107,239 | $589,275 | $124,244 | 6.2% | |
| Other employee benefits | $8,713,053 | $7,263,485 | $1,252,448 | $197,120 | 5.5% | |
| Other (as described) | Scientific collaborations | $6,324,867 | $6,324,867 | - | - | 4.0% |
| Interest | $4,030,913 | $3,659,666 | $333,356 | $37,891 | 2.5% | |
| Pension plan contributions | $3,909,187 | $3,121,685 | $691,364 | $96,138 | 2.5% | |
| Pay: officers, directors, trustees, key employees | $3,820,675 | $2,332,592 | $1,488,083 | - | 2.4% | |
| Payroll taxes | $3,811,875 | $3,081,173 | $621,288 | $109,414 | 2.4% | |
| Information technology | $1,741,934 | $1,238,920 | $495,559 | $7,455 | 1.1% | |
| Fees: legal | $1,566,460 | $61,955 | $1,504,505 | - | 1.0% | |
| Conferences, conventions and meetings | $1,477,921 | $1,058,675 | $362,528 | $56,718 | 0.9% | |
| Fees: management | $1,298,851 | $1,093,605 | $205,211 | $35 | 0.8% | |
| Travel | $874,746 | $735,935 | $110,666 | $28,145 | 0.6% | |
| Fees: other services | $808,701 | $453,669 | $222,301 | $132,731 | 0.5% | |
| Fees: accounting | $498,836 | - | $498,836 | - | 0.3% | |
| Other (as described) | Miscellaneous | $426,334 | $126,007 | $114,129 | $186,198 | 0.3% |
| Other (as described) | Recruitment | $349,094 | $181,481 | $53,369 | $114,244 | 0.2% |
| Fees: professional fundraisers | $196,445 | - | - | $196,445 | 0.1% | |
| Fees: lobbying | $126,038 | - | $126,038 | - | 0.1% | |
| Insurance | $53,377 | - | $53,377 | - | 0.0% | |
| Advertising and promotion | $44,857 | - | $6,656 | $38,201 | 0.0% | |
| Fundraising events Event | direct expenses; gross income - | $516,839 | reported apart | |||
| Total | $158,377,766 | 100% |
2010 · Form 990 · $161,165,052 spent · pay $82,307,396 · grants $0 · events $2,011,922
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $62,616,458 | $51,626,280 | $9,228,335 | $1,761,843 | 38.9% | |
| Depreciation and depletion | $19,735,677 | $17,140,216 | $2,406,262 | $189,199 | 12.2% | |
| Occupancy | $13,565,937 | $12,063,385 | $1,375,834 | $126,718 | 8.4% | |
| Other (as described) | RESEARCH SUPPLIES & SERVICES | $12,682,026 | $12,682,026 | - | - | 7.9% |
| Office expenses | $9,427,632 | $8,605,761 | $634,503 | $187,368 | 5.8% | |
| Other employee benefits | $8,786,127 | $7,063,490 | $1,516,249 | $206,388 | 5.5% | |
| Other (as described) | SCIENTIFIC COLLABORATIONS | $6,426,098 | $6,426,098 | - | - | 4.0% |
| Interest | $4,317,034 | $3,912,960 | $363,494 | $40,580 | 2.7% | |
| Payroll taxes | $3,865,752 | $3,105,928 | $649,624 | $110,200 | 2.4% | |
| Pension plan contributions | $3,537,594 | $2,742,477 | $684,684 | $110,433 | 2.2% | |
| Pay: officers, directors, trustees, key employees | $3,501,465 | $1,625,080 | $1,876,385 | - | 2.2% | |
| Fees: legal | $2,542,522 | $136,000 | $2,406,522 | - | 1.6% | |
| Information technology | $1,998,758 | $1,458,225 | $466,857 | $73,676 | 1.2% | |
| Fees: other services | $1,787,582 | $1,185,217 | $448,643 | $153,722 | 1.1% | |
| Conferences, conventions and meetings | $1,597,112 | $1,029,398 | $464,628 | $103,086 | 1.0% | |
| Fees: management | $1,523,488 | $1,115,182 | $315,513 | $92,793 | 0.9% | |
| Travel | $863,319 | $689,441 | $138,321 | $35,557 | 0.5% | |
| Other (as described) | RECRUITMENT | $823,817 | $723,955 | $73,370 | $26,492 | 0.5% |
| Other (as described) | MISCELLANEOUS | $743,108 | $162,353 | $406,624 | $174,131 | 0.5% |
| Fees: accounting | $389,980 | - | $389,980 | - | 0.2% | |
| Fees: lobbying | $242,981 | - | $242,981 | - | 0.2% | |
| Advertising and promotion | $119,958 | $296 | $36,285 | $83,377 | 0.1% | |
| Insurance | $70,627 | - | $70,627 | - | 0.0% | |
| Fundraising events Event | direct expenses; gross income - | $414,810 | reported apart | |||
| Total | $161,165,052 | 100% |
Federal grants and contracts
Awards from USAspending.gov to a recipient with this organization's name and zip code. Obligations by federal fiscal year (October to September); each award links to its page on usaspending.gov.
| Fiscal year | Grants and other assistance | Contracts | Awards |
|---|---|---|---|
| 2027 | $0 | $0 | 1 |
| 2026 | $48,962,706 | $0 | 84 |
| 2025 | $44,448,623 | $0 | 81 |
| 2024 | $55,764,052 | $0 | 104 |
| 2023 | $56,152,013 | $0 | 97 |
| 2022 | $69,783,904 | $0 | 115 |
| 2021 | $57,948,230 | $0 | 121 |
| 2020 | $64,548,414 | -$4,842 | 121 |
| 2019 | $58,009,298 | $100,000 | 127 |
| 2018 | $57,224,036 | $5,249 | 116 |
| 2017 | $67,759,193 | $84,842 | 154 |
| 2016 | $56,229,930 | $0 | 114 |
| 2015 | $50,916,738 | $5,242 | 113 |
| 2014 | $63,218,001 | $0 | 123 |
| 2013 | $56,109,949 | $9,201 | 128 |
| 2012 | $75,749,103 | $0 | 131 |
| 2011 | $77,065,944 | $3,627 | 130 |
| 2010 | $84,413,434 | $0 | 140 |
| 2009 | $82,061,644 | $0 | 125 |
| 2008 | $59,603,118 | $35,000 | 73 |
| 2007 | $46,931,303 | $0 | 88 |
Largest awards · 200 shown
| Year | Agency | Kind | Program | Description | Obligated |
|---|---|---|---|---|---|
| 2026 | National Institutes of Health | Grant or other assistance | CANCER CENTERS SUPPORT GRANTS 93.397 | CANCER CENTER SUPPORT GRANT | $4,081,820 |
| 2026 | National Institutes of Health | Grant or other assistance | DRUG USE AND ADDICTION RESEARCH PROGRAMS 93.279 | NEUROTENSIN 1 ALLOSTERIC MODULATOR FOR THE TREATMENT OF PAIN - PROJECT SUMMARY THE NIH HEAL INITIATIVE AIMS TO TACKLE TWO ONGOING HEALTH CARE CRISES: OPIOID USE | $3,855,681 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | MOLECULAR BASIS OF NUCLEAR PORE FORMATION - PROJECT SUMMARY NUCLEAR PORE COMPLEXES (NPCS) ARE ESSENTIAL PROTEIN ASSEMBLIES THAT CONTROL SELECTIVE TRANSPORT BETW | $2,903,176 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | DISCOVERY AND OPTIMIZATION OF APOE4 CORRECTORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE - PROJECT SUMMARY ALZHEIMER'S DISEASE (AD) IS A MAJOR PUBLIC HEALTH CRIS | $2,676,401 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | ROLE OF HYPERNUTRITION AND METABOLIC STRESS IN NON-ALCOHOLIC STEATOHEPATITIS (NASH) DRIVEN HEPATOCELLULAR CARCINOMA (HCC) - PROJECT SUMMARY – OVERALL HEPATOCELL | $2,272,153 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | REWIRING T CELL EXHAUSTION WITH IMMUNE CHECKPOINT BLOCKADE THERAPY - PROJECT SUMMARY THE GOAL OF THIS PROJECT IS TO DETERMINE WHETHER IT IS POSSIBLE TO PROMOTE | $2,024,989 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | CATALYTIC MECHANISMS, REGULATION, AND ANTI-FIBROTIC ROLES OF THE TMEM2 CELL SURFACE HYALURONIDASE - PROJECT SUMMARY HYALURONAN (HA), A MEMBER OF THE GLYCOSAMINO | $1,677,007 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | SINGLE-CONSTRUCT GENE THERAPY FOR ENHANCED HEART REPAIR - PROJECT SUMMARY CARDIOVASCULAR DISEASES ARE THE LEADING CAUSE OF DEATH GLOBALLY, RESPONSIBLE FOR NEARL | $1,603,648 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | REGULATION OF PDAC METABOLISM AND IMMUNITY BY COLLAGEN AND ITS CLEAVAGE PRODUCTS - ABSTRACT PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) IS A HIGHLY DESMOPLASTIC AND | $1,021,269 |
| 2026 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | POST-TRANSCRIPTIONAL REGULATION BY RNA BINDING PROTEINS IN LIVER FIBROSIS - PROJECT SUMMARY CHRONIC LIVER INJURY CAN LEAD TO FIBROSIS, A CONDITION WHERE SCAR TI | $910,940 |
| 2026 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | THE NRF2-FBP1 CROSSREGULATORY LOOP AND THE CONTROL OF HEALTHY AND DISEASED LIVER METABOLISM - PROJECT SUMMARY/ABSTRACT FRUCTOSE BISPHOSPHATE PHOSPHATASE (FBP1) | $889,840 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | MOLECULAR PATHOBIOLOGY OF SOLUBLE TREM2 IN ALZHEIMER'S DISEASE - PROJECT SUMMARY ALZHEIMER’S DISEASE (AD) IS THE MOST PROMINENT NEURODEGENERATIVE DISORDER WORL | $880,491 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | NOVEL NEUROPROTECTIVE ROLES FOR THE ALZHEIMER'S DISEASE RISK GENE SORLA IN TAU PATHOLOGY AND PATHOGENESIS - NUMEROUS MUTATIONAL VARIANTS IN THE SORLA (SORL1) GE | $877,445 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | ELUCIDATING A MICROGLIAASSOCIATED ROLE FOR SORLA IN MODULATING AD PATHOGENESIS - PROJECT SUMMARY MUTATIONS IN SORLA (ENCODED BY SORL1) IDENTIFIED THROUGH GWAS | $865,606 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | NF-KAPPAB AND MITOCHONDRIAL SIGNALS AS POSITIVE AND NEGATIVE REGULATORS OF INFLAMMATION | $815,131 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | COLLAGEN FIBERS AND FRAGMENTS REGULATE PANCREATIC CANCER METABOLISM AND GROWTH. - PROJECT SUMMARY PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) IS CHARACTERIZED BY EX | $809,870 |
| 2026 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | NEW CONGENITAL DISORDERS OF GLYCOSYLATION: THERAPY AND MODELS | $809,568 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | DISCOVERY OF POTENT SELECTIVE INHIBITORS OF THE HISTONE METHYLTRANSFERASE SUV39H1 FOR THE TREATMENT OF CANCER - PROJECT SUMMARY CANCER TREATMENT HAS BEEN TRANSF | $809,234 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | CHARACTERIZING THE FUNCTIONS OF NUP210 IN LEUKEMIA - PROJECT SUMMARY NUCLEAR PORE COMPLEXES (NPCS) ARE LARGE MULTIPROTEIN CHANNELS THAT CONNECT THE NUCLEUS WITH | $803,681 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | SCREENING FOR INHIBITORS OF THE CHROMATIN READER SGF29 - PROJECT SUMMARY AML IS A DEVASTATING DISEASE WITH SURVIVAL RATES OF ONLY 30-35 PERCENT AND CURE-RATES H | $772,588 |
| 2026 | National Institutes of Health | Grant or other assistance | ALCOHOL RESEARCH PROGRAMS 93.273 | OPTIMIZATION OF DRUG-LIKE PROPERTIES OF CRFBP-CRF2 NEGATIVE ALLOSTERIC MODULATORS FOR ALCOHOL USE DISORDER - PROJECT SUMMARY THIS APPLICATION, “OPTIMIZATION OF | $771,544 |
| 2026 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | IMPROVING PROINSULIN FOLDING TO AMELIORATE TYPE II DIABETES - PROJECT SUMMARY DIABETES IS AMONG THE FASTEST GROWING HEALTH CHALLENGES OF THE 21ST CENTURY, AFFEC | $760,498 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | AGING AS A RISK FACTOR AND TARGET FOR PREVENTION OF LIVER CANCER - PROJECT SUMMARY – OVERALL THE INCIDENCES OF LIVER CANCER (PRIMARILY HEPATOCELLULAR CARCINOMA | $758,616 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | COMPARATIVE RESISTOMICS OF GRAM-NEGATIVE BACTERIAL PATHOGENS - ABSTRACT INCREASING ANTIBIOTIC RESISTANCE NECESSITATES EXPANDING RESEARCH INTO THE MECHANISMS BY | $733,500 |
| 2026 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | CONTROL OF LIPOGENESIS AND HEPATIC STEATOSIS BY CASPASE-2 | $722,374 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | A NEW MOUSE MODEL FOR STUDYING THE PATHOGENESIS AND IMMUNOBIOLOGY OF INTRAHEPATIC CHOLANGIOCARCINOMA AND IMPROVING ITS IMMUNOTHERAPY - ABSTRACT INTRAHEPATIC CHO | $695,955 |
| 2026 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | DETERMINING THE STOICHIOMETRY OF ENDOGENOUS VOLTAGE-GATED POTASSIUM CHANNELS IN THE BRAIN - PROJECT SUMMARY FOR NEURONS TO ACT AS THE BASIC UNIT OF INFORMATION | $670,380 |
| 2026 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | DISSECTING THE INTRACELLULAR AND EXTRACELLULAR ROLE OF TREM2 IN THE PATHOGENESIS OF NON-ALCOHOLIC STEATOHEPATITIS. - ABSTRACT: NON-ALCOHOLIC STEATOHEPATITIS (NA | $664,854 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | TRANSCRIPTIONAL REPROGRAMMING OF ANTI-TUMOR IMMUNITY - PROJECT SUMMARY IMMUNE CHECKPOINT BLOCKADE THERAPIES HAVE GARNERED EXCITEMENT DUE TO THEIR ABILITY TO IND | $646,134 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | DISCOVERY OF NOVEL INHIBITORS TARGETING TRANS-GOLGI NETWORK ACIDIFICATION IN PANCREATIC CANCER - PROJECT SUMMARY PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) IS PRO | $645,540 |
| 2026 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | INVESTIGATION OF ECDNA AS A DRIVER OF INTRATUMORAL HETEROGENEITY AND TREATMENT RESISTANCE IN HIGH-RISK MEDULLOBLASTOMA - THE OVERALL OBJECTIVE OF THIS PROPOSAL | $636,772 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | SPECTRAL CELL SORTER - PROJECT SUMMARY/ABSTRACT THIS S10 APPLICATION REQUESTS A CYTEK AURORA CS SPECTRAL CELL SORTER FOR SANFORD BURNHAM PREBYS (SBP) TO REPLACE | $632,113 |
| 2026 | National Institutes of Health | Grant or other assistance | TRANS-NIH RESEARCH SUPPORT 93.310 | SPATIAL MAPPING SENESCENT CELLS ACROSS THE MOUSE LIFESPAN BY MULTIPLEX TRANSCRIPTOMICS AND EPIGENOMICS - PROJECT SUMMARY CELLULAR SENESCENCE, CHARACTERIZED BY S | $630,884 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | EPHA2 RECEPTOR SIGNALING IN BREAST CANCER MECHANOTRANSDUCTION - SUMMARY MECHANICAL FORCES GENERATED BY A RIGID EXTRACELLULAR MATRIX (ECM) IN THE TUMOR MICROENVI | $623,932 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | HORMETIC REGULATION OF AUTOPHAGY IN AGING - PROJECT SUMMARY AUTOPHAGY DEGRADES CYTOSOLIC MATERIAL, SUCH AS AGGREGATED PROTEINS, VIA THE FORMATION OF AUTOPHAGOSO | $586,599 |
| 2026 | National Institutes of Health | Grant or other assistance | DRUG USE AND ADDICTION RESEARCH PROGRAMS 93.279 | BRAIN-PENETRANT GPR88 AGONISTS AS NOVEL THERAPEUTICS FOR OPIOID ABUSE - SUMMARY SUBMITTED IN RESPONSE TO RFA-DA-22-031, THIS APPLICATION DESCRIBES A MULTIDISCIP | $581,970 |
| 2026 | National Institutes of Health | Grant or other assistance | ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 | EPIGENETICS & SIGNALING IN HESC COMMITMENT AND DIFFERENTIATION INTO MUSCLE | $581,203 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | MICROGLIAL HEPARAN SULFATE IN THE MODULATION OF APOE FUNCTION AND NEURODEGENERATION - HEPARAN SULFATE (HS), A SULFATED GLYCAN EXPRESSED AT THE CELL SURFACE AND | $580,960 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | MACROPINOCYTOSIS INHIBITION AS A GLUTAMINE MIMETIC SENSITIZATION STRATEGY IN PANCREATIC CANCER - PROJECT SUMMARY PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) CELLS D | $565,933 |
| 2026 | National Institutes of Health | Grant or other assistance | NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 | TARGETING GATA3 AS A THERAPEUTIC STRATEGY IN TH2-DRIVEN DISEASES - PROJECT SUMMARY ULCERATIVE COLITIS (UC) IS THE MOST COMMON FORM OF INFLAMMATORY BOWEL DISEASE | $536,250 |
| 2026 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | UBIQUITIN D AS A POTENTIAL THERAPEUTIC TARGET FOR NASH, HCC AND CHRONIC KIDNEY DISEASES - ABSTRACT: NON-ALCOHOLIC STEATOHEPATITIS (NASH), AN ADVANCED FORM OF NO | $500,000 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | REGULATION OF BLOOD GLYCOPROTEINS BY LECTIN RECEPTORS IN HEALTH AND DISEASE - SUMMARY THE COMPOSITION OF THE BLOOD PROTEOME PROVIDES INDICATIONS OF NORMAL HEALT | $487,500 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | MOLECULAR MECHANISMS UNDERLYING THE ASSEMBLY OF THE HUMAN PROTEASOME AND ENDOGENOUS PROTEIN COMPLEXES - PROJECT SUMMARY ADVANCES IN STRUCTURAL BIOLOGY TECHNIQUE | $487,500 |
| 2026 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | GLYCOSYLTRANSFERASE FUNCTION IN DEVELOPMENT AND DISEASE | $487,500 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | LIGAND FUNCTIONAL SELECTIVITY IN EPHA2 RECEPTOR SIGNALING | $476,742 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | MOLECULAR PATHOGENESIS OF AF10-REARRANGED LEUKEMIAS - PROJECT SUMMARY THERE HAS BEEN CONSIDERABLE PROGRESS IN THE LAST FEW YEARS IN THE CHARACTERIZATION OF MOLE | $450,287 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | TARGETING THE FBXO44/SUV39H1 PATHWAY IN CANCER - PROJECT SUMMARY REPETITIVE ELEMENTS (RES) COMPOSE ~45% OF THE HUMAN GENOME AND ARE NORMALLY TRANSCRIPTIONALLY S | $446,063 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | TARGETING ER+ BREAST CANCER THROUGH INDUCED VIRAL MIMICRY - PROJECT SUMMARY REPETITIVE ELEMENTS (RES) COMPOSE ~45% OF THE HUMAN GENOME AND ARE NORMALLY TRANSCRI | $446,063 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | EPIGENETIC REPROGRAMMING TO COUNTERACT NEURONAL AGING AND DEGENERATION - PROJECT SUMMARY/ABSTRACT THE AGING BRAIN IS INCREASINGLY SUSCEPTIBLE TO COGNITIVE DECLI | $248,999 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | IMMUNE CHECKPOINT BLOCKADE TARGETING THE NOVEL PSGL-1/VISTA AXIS FOR PANCREATIC CANCER - PROJECT SUMMARY THE GOAL OF THIS PROJECT IS TO DEVELOP A NOVEL IMMUNOTH | $209,674 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | DEVELOPMENT AND IMPLEMENTATION OF ADVANCED TECHNOLOGIES FOR CANCER METABOLISM RESEARCH - PROJECT SUMMARY THIS PROPOSAL REQUESTS SUPPORT FOR MY POSITION AS THE D | $142,032 |
| 2026 | Defense Health Agency | Grant or other assistance | MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 | TARGETING GLIOBLASTOMA WITH A FIRST-IN-CLASS BRD8 MOLECULAR GLUE DEGRADER AND TEMOZOLOMIDE | $140,000 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER RESEARCH MANPOWER 93.398 | ROLE OF P2X4 RECEPTORS IN GOLGI PH REGULATION IN PANCREATIC CANCER - PROJECT SUMMARY PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) IS AMONG THE MOST LETHAL CANCERS, I | $46,714 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER RESEARCH MANPOWER 93.398 | PIKFYVE REGULATES PH HOMEOSTASIS AND TUMOR GROWTH IN PANCREATIC CANCER - PROJECT SUMMARY THE CURRENT OVERALL 5-YEAR SURVIVAL RATE FOR PANCREATIC DUCTAL ADENOCAR | $41,386 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | ETS TRANSCRIPTION FACTORS AS CARDIAC MAINTENANCE REGULATORS: LINKING RAF-ERK-PNT SIGNALING TO ADULT CARDIAC HYPERTROPHY - PROJECT SUMMARY HYPERTROPHIC CARDIOMYO | $38,314 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | DISCOVERY OF GLUTARYL-COA DEHYDROGENASE INHIBITORS FOR MELANOMA AND PANCREATIC CANCER - PROJECT SUMMARY MELANOMA IS AN EXTREMELY AGGRESSIVE CANCER WITH HIGH MOR | $0 |
| 2026 | Defense Health Agency | Grant or other assistance | MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 | THERAPEUTIC TARGETING OF A LIPID KINASE REGULATOR OF MUTANT P53 IN BREAST CANCER | $0 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | DISCOVERY OF SMALL MOLECULE REGULATORS OF ATRIAL CARDIOMYOCYTE ACTION POTENTIAL DURATION TO RESTORE NORMAL CARDIAC RHYTHM IN ATRIAL FIBRILLATION - PROJECT SUMMA | $0 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | PROTEIN SIALYLATION AND DE-SIALYATION IN CELL SURFACE GLYCOPROTEIN HOMEOSTASIS AND DISEASE - SUMMARY PROTEIN SIALYLATION IS A POST-TRANSLATIONAL MODIFICATION PR | $0 |
| 2026 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | SPATIAL REGULATORS OF SKELETAL MUSCLE REGENERATION AND DISEASE - SKELETAL MUSCLES ARE RESPONSIBLE FOR MOVEMENT, BREATHING, POSTURE AND METABOLISM. LOSS OF MUSCL | -$20 |
| 2026 | National Institutes of Health | Grant or other assistance | DRUG USE AND ADDICTION RESEARCH PROGRAMS 93.279 | CLINICAL DEVELOPMENT OF AN MGLU2 POSITIVE ALLOSTERIC MODULATOR TO TREAT NICOTINE ADDICTION | -$214 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | PRECLINICAL DISCOVERY OF NOVEL FARNESYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND RELATED TAUOPATHIES - PROJECT SUMMARY ALZHEIMER’S DI | -$368 |
| 2026 | National Institutes of Health | Grant or other assistance | TRANS-NIH RESEARCH SUPPORT 93.310 | TRANSFORMATIVE RESEARCH ON SOMATIC GENE RECOMBINATION IN THE NORMAL AND ALZHEIMER'S DISEASE-RELATED DEMENTIA BRAIN | -$1,448 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | PROTEIN GLYCOSYLATION IN THE COAGULOPATHY AND INFLAMMATION OF SEPSIS | -$3,021 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | OVERRIDING THE IMMUNE EVASION TACTICS OF CORONAVIRUS | -$6,095 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | ALTERED REVERSE TRANSCRIPTASE-DEPENDENT GENE DIVERSIFICATION MECHANISMS IN ALZHEIMER'S DISEASE BRAINS | -$13,983 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | OPTIMIZATION OF FIBROBLAST-SELECTIVE INHIBITORS OF YAP/TAZ AS NOVEL THERAPEUTICS FOR PULMONARY FIBROSIS - PROJECT SUMMARY IDIOPATHIC PULMONARY FIBROSIS IS A CHR | -$47,464 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER CENTERS SUPPORT GRANTS 93.397 | CANCER CENTER SUPPORT GRANT | $4,276,818 |
| 2025 | National Institutes of Health | Grant or other assistance | TRANS-NIH RESEARCH SUPPORT 93.310 | SPATIAL MAPPING SENESCENT CELLS ACROSS THE MOUSE LIFESPAN BY MULTIPLEX TRANSCRIPTOMICS AND EPIGENOMICS - PROJECT SUMMARY CELLULAR SENESCENCE, CHARACTERIZED BY S | $2,889,150 |
| 2025 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | PROTEIN GLYCOSYLATION IN THE COAGULOPATHY AND INFLAMMATION OF SEPSIS | $2,674,150 |
| 2025 | National Institutes of Health | Grant or other assistance | DRUG USE AND ADDICTION RESEARCH PROGRAMS 93.279 | SAFETY/TOXICOLOGY, ADME AND CMC ACTIVITIES TO SUPPORT THE ASSESSMENT OF THE MGLU2 PAM SBP-9330 IN A PHASE 2 CLINICAL STUDY IN SMOKERS - PROJECT SUMMARY THIS RES | $2,652,771 |
| 2025 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | AGING AS A RISK FACTOR AND TARGET FOR PREVENTION OF LIVER CANCER - PROJECT SUMMARY – OVERALL THE INCIDENCES OF LIVER CANCER (PRIMARILY HEPATOCELLULAR CARCINOMA | $2,530,091 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | ROLE OF HYPERNUTRITION AND METABOLIC STRESS IN NON-ALCOHOLIC STEATOHEPATITIS (NASH) DRIVEN HEPATOCELLULAR CARCINOMA (HCC) - PROJECT SUMMARY – OVERALL HEPATOCELL | $2,302,833 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | REGULATION OF PDAC METABOLISM AND IMMUNITY BY COLLAGEN AND ITS CLEAVAGE PRODUCTS - ABSTRACT PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) IS A HIGHLY DESMOPLASTIC AND | $1,262,768 |
| 2025 | Defense Health Agency | Grant or other assistance | MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 | A CHEMICAL ENGINEERING APPROACH TO ALS THAT AMPLIFIES A MORE SOPHISTICATED VIEW OF THE MULTIMODAL THERAPEUTIC ACTIONS OF DONOR AND HOST NEURAL STEM CELLS IN THA | $1,078,882 |
| 2025 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | ELUCIDATING A MICROGLIAASSOCIATED ROLE FOR SORLA IN MODULATING AD PATHOGENESIS - PROJECT SUMMARY MUTATIONS IN SORLA (ENCODED BY SORL1) IDENTIFIED THROUGH GWAS | $867,404 |
| 2025 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | PRECLINICAL DISCOVERY OF NOVEL FARNESYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND RELATED TAUOPATHIES - PROJECT SUMMARY ALZHEIMER’S DI | $857,439 |
| 2025 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | NOVEL NEUROPROTECTIVE ROLES FOR THE ALZHEIMER'S DISEASE RISK GENE SORLA IN TAU PATHOLOGY AND PATHOGENESIS - NUMEROUS MUTATIONAL VARIANTS IN THE SORLA (SORL1) GE | $846,520 |
| 2025 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | NEW CONGENITAL DISORDERS OF GLYCOSYLATION: THERAPY AND MODELS | $809,568 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | DISCOVERY OF POTENT SELECTIVE INHIBITORS OF THE HISTONE METHYLTRANSFERASE SUV39H1 FOR THE TREATMENT OF CANCER - PROJECT SUMMARY CANCER TREATMENT HAS BEEN TRANSF | $809,248 |
| 2025 | National Institutes of Health | Grant or other assistance | ALCOHOL RESEARCH PROGRAMS 93.273 | OPTIMIZATION OF DRUG-LIKE PROPERTIES OF CRFBP-CRF2 NEGATIVE ALLOSTERIC MODULATORS FOR ALCOHOL USE DISORDER - PROJECT SUMMARY THIS APPLICATION, “OPTIMIZATION OF | $786,961 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | SCREENING FOR INHIBITORS OF THE CHROMATIN READER SGF29 - PROJECT SUMMARY AML IS A DEVASTATING DISEASE WITH SURVIVAL RATES OF ONLY 30-35 PERCENT AND CURE-RATES H | $768,437 |
| 2025 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | IMPROVING PROINSULIN FOLDING TO AMELIORATE TYPE II DIABETES - PROJECT SUMMARY DIABETES IS AMONG THE FASTEST GROWING HEALTH CHALLENGES OF THE 21ST CENTURY, AFFEC | $760,498 |
| 2025 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | COMPARATIVE RESISTOMICS OF GRAM-NEGATIVE BACTERIAL PATHOGENS - ABSTRACT INCREASING ANTIBIOTIC RESISTANCE NECESSITATES EXPANDING RESEARCH INTO THE MECHANISMS BY | $733,500 |
| 2025 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | DISCOVERY AND OPTIMIZATION OF APOE4 CORRECTORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE - PROJECT SUMMARY ALZHEIMER'S DISEASE (AD) IS A MAJOR PUBLIC HEALTH CRIS | $689,010 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | REWIRING T CELL EXHAUSTION WITH IMMUNE CHECKPOINT BLOCKADE THERAPY - PROJECT SUMMARY THE GOAL OF THIS PROJECT IS TO DETERMINE WHETHER IT IS POSSIBLE TO PROMOTE | $674,996 |
| 2025 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | DISSECTING THE INTRACELLULAR AND EXTRACELLULAR ROLE OF TREM2 IN THE PATHOGENESIS OF NON-ALCOHOLIC STEATOHEPATITIS. - ABSTRACT: NON-ALCOHOLIC STEATOHEPATITIS (NA | $665,028 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | DISCOVERY OF NOVEL INHIBITORS TARGETING TRANS-GOLGI NETWORK ACIDIFICATION IN PANCREATIC CANCER - PROJECT SUMMARY PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) IS PRO | $645,331 |
| 2025 | National Institutes of Health | Grant or other assistance | DRUG USE AND ADDICTION RESEARCH PROGRAMS 93.279 | BRAIN-PENETRANT GPR88 AGONISTS AS NOVEL THERAPEUTICS FOR OPIOID ABUSE - SUMMARY SUBMITTED IN RESPONSE TO RFA-DA-22-031, THIS APPLICATION DESCRIBES A MULTIDISCIP | $644,048 |
| 2025 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | INVESTIGATION OF ECDNA AS A DRIVER OF INTRATUMORAL HETEROGENEITY AND TREATMENT RESISTANCE IN HIGH-RISK MEDULLOBLASTOMA - THE OVERALL OBJECTIVE OF THIS PROPOSAL | $636,772 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | EPHA2 RECEPTOR SIGNALING IN BREAST CANCER MECHANOTRANSDUCTION - SUMMARY MECHANICAL FORCES GENERATED BY A RIGID EXTRACELLULAR MATRIX (ECM) IN THE TUMOR MICROENVI | $623,123 |
| 2025 | National Institutes of Health | Grant or other assistance | ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 | MECHANISMS THAT COUPLE IRREGULAR DEVELOPMENT OF FETAL MELANOBLASTS TO PREMATURE EXHAUSTION OF ADULT MELANOCYTE STEM CELLS - PROJECT SUMMARY MAINTENANCE OF TISSU | $619,779 |
| 2025 | National Institutes of Health | Grant or other assistance | ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 | ROLE OF FBXW7-MEDIATED PROTEASOMAL DEGRADATION IN MYOFIBERS IN DETERMINING MUSCLE STEM CELL POOL SIZE | $586,260 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | REGULATION AND FUNCTION OF STROMAL MACROPINOCYTOSIS IN PANCREATIC DUCTAL ADENOCARCINOMA - PROJECT SUMMARY RECENT YEARS HAVE WITNESSED AN APPRECIATION OF THE ROL | $585,801 |
| 2025 | National Institutes of Health | Grant or other assistance | ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 | EPIGENETICS & SIGNALING IN HESC COMMITMENT AND DIFFERENTIATION INTO MUSCLE | $575,324 |
| 2025 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | HORMETIC REGULATION OF AUTOPHAGY IN AGING - PROJECT SUMMARY AUTOPHAGY DEGRADES CYTOSOLIC MATERIAL, SUCH AS AGGREGATED PROTEINS, VIA THE FORMATION OF AUTOPHAGOSO | $574,868 |
| 2025 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | MICROGLIAL HEPARAN SULFATE IN THE MODULATION OF APOE FUNCTION AND NEURODEGENERATION - HEPARAN SULFATE (HS), A SULFATED GLYCAN EXPRESSED AT THE CELL SURFACE AND | $569,341 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | MACROPINOCYTOSIS INHIBITION AS A GLUTAMINE MIMETIC SENSITIZATION STRATEGY IN PANCREATIC CANCER - PROJECT SUMMARY PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) CELLS D | $565,933 |
| 2025 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | FUNCTION AND MECHANISM OF THE HIPPO-PI5P4K AXIS FOR GROWTH CONTROL - PROJECT SUMMARY OUR LONG-TERM GOAL IS TO DECIPHER THE MOLECULAR MECHANISMS UNDERLYING PI5P4 | $555,975 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | DISCOVERY OF GLUTARYL-COA DEHYDROGENASE INHIBITORS FOR MELANOMA AND PANCREATIC CANCER - PROJECT SUMMARY MELANOMA IS AN EXTREMELY AGGRESSIVE CANCER WITH HIGH MOR | $538,890 |
| 2025 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | A KNOWLEDGE-GUIDED ANALYSIS APPROACH TO RECOVERING RARE SIGNALS FROM SINGLE-CELL TRANSCRIPTOMIC DATA - PROJECT SUMMARY THIS INNOVATIVE PROJECT AIMS AT DEVELOPIN | $536,250 |
| 2025 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | LIGAND FUNCTIONAL SELECTIVITY IN EPHA2 RECEPTOR SIGNALING | $508,048 |
| 2025 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | UBIQUITIN D AS A POTENTIAL THERAPEUTIC TARGET FOR NASH, HCC AND CHRONIC KIDNEY DISEASES - ABSTRACT: NON-ALCOHOLIC STEATOHEPATITIS (NASH), AN ADVANCED FORM OF NO | $500,000 |
| 2025 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | GLYCOSYLTRANSFERASE FUNCTION IN DEVELOPMENT AND DISEASE | $487,500 |
| 2025 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | REGULATION OF BLOOD GLYCOPROTEINS BY LECTIN RECEPTORS IN HEALTH AND DISEASE - SUMMARY THE COMPOSITION OF THE BLOOD PROTEOME PROVIDES INDICATIONS OF NORMAL HEALT | $487,500 |
| 2025 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | MOLECULAR MECHANISMS UNDERLYING THE ASSEMBLY OF THE HUMAN PROTEASOME AND ENDOGENOUS PROTEIN COMPLEXES - PROJECT SUMMARY ADVANCES IN STRUCTURAL BIOLOGY TECHNIQUE | $487,500 |
| 2025 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | PROTEIN SIALYLATION AND DE-SIALYATION IN CELL SURFACE GLYCOPROTEIN HOMEOSTASIS AND DISEASE - SUMMARY PROTEIN SIALYLATION IS A POST-TRANSLATIONAL MODIFICATION PR | $472,875 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | REGULATION OF NUTRIENT STRESS-INDUCED MACROPINOCYTOSIS IN PANCREATIC DUCTAL ADENOCARCINOMA | $466,136 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | MOLECULAR PATHOGENESIS OF AF10-REARRANGED LEUKEMIAS - PROJECT SUMMARY THERE HAS BEEN CONSIDERABLE PROGRESS IN THE LAST FEW YEARS IN THE CHARACTERIZATION OF MOLE | $449,276 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | TARGETING THE FBXO44/SUV39H1 PATHWAY IN CANCER - PROJECT SUMMARY REPETITIVE ELEMENTS (RES) COMPOSE ~45% OF THE HUMAN GENOME AND ARE NORMALLY TRANSCRIPTIONALLY S | $446,063 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | TARGETING ER+ BREAST CANCER THROUGH INDUCED VIRAL MIMICRY - PROJECT SUMMARY REPETITIVE ELEMENTS (RES) COMPOSE ~45% OF THE HUMAN GENOME AND ARE NORMALLY TRANSCRI | $446,063 |
| 2025 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | AUGMENTED NOTCH SIGNALING AS A THERAPEUTIC APPROACH FOR ALAGILLE SYNDROME - PROJECT SUMMARY ALAGILLE SYNDROME (ALGS) IS AN AUTOSOMAL DOMINANT DISORDER CHARACTER | $433,179 |
| 2025 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | CYTOPLASMIC CHROMATIN FRAGMENTS IN CELL SENESCENCE - NOVEL MECHANISMS AND INTERVENTIONS - PROJECT SUMMARY CELLULAR SENESCENCE IS A CAUSE OF CELL AND TISSUE AGIN | $419,931 |
| 2025 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | IDENTIFICATION OF MICROPROTEINS ASSOCIATED WITH HEMATOPOIESIS AND RELATED DISEASES - PROJECT SUMMARY THIS INNOVATIVE, INTER-DISCIPLINARY PROJECT AIMS AT DISCOVE | $292,500 |
| 2025 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | THE AGING PANCREAS AS A PRO-TUMORIGENIC NICHE - PROJECT SUMMARY AGE IS A MAJOR RISK FACTOR FOR PANCREATIC DUCTAL ADENOCARCINOMA (PDAC), WITH THE INCIDENCE OF PD | $292,500 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | IMMUNE CHECKPOINT BLOCKADE TARGETING THE NOVEL PSGL-1/VISTA AXIS FOR PANCREATIC CANCER - PROJECT SUMMARY THE GOAL OF THIS PROJECT IS TO DEVELOP A NOVEL IMMUNOTH | $268,345 |
| 2025 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | SPATIAL REGULATORS OF SKELETAL MUSCLE REGENERATION AND DISEASE - SKELETAL MUSCLES ARE RESPONSIBLE FOR MOVEMENT, BREATHING, POSTURE AND METABOLISM. LOSS OF MUSCL | $248,721 |
| 2025 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | EPIGENETIC REPROGRAMMING TO COUNTERACT NEURONAL AGING AND DEGENERATION - PROJECT SUMMARY/ABSTRACT THE AGING BRAIN IS INCREASINGLY SUSCEPTIBLE TO COGNITIVE DECLI | $244,019 |
| 2025 | Defense Health Agency | Grant or other assistance | MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 | FUNCTION AND THERAPEUTIC POTENTIAL OF R LOOPS IN GLIOBLASTOMA | $195,000 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | DEVELOPMENT AND IMPLEMENTATION OF ADVANCED TECHNOLOGIES FOR CANCER METABOLISM RESEARCH - PROJECT SUMMARY THIS PROPOSAL REQUESTS SUPPORT FOR MY POSITION AS THE D | $142,032 |
| 2025 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | FRAGMENT-BASED DISCOVERY OF STEP MODULATORS IN ALZHEIMER'S DISEASE ADMINISTRATIVE SUPPLEMENT - PROJECT SUMMARY STRIATAL-ENRICHED TYROSINE PHOSPHATASE (STEP) IS | $111,976 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER RESEARCH MANPOWER 93.398 | PIKFYVE REGULATES PH HOMEOSTASIS AND TUMOR GROWTH IN PANCREATIC CANCER - PROJECT SUMMARY THE CURRENT OVERALL 5-YEAR SURVIVAL RATE FOR PANCREATIC DUCTAL ADENOCAR | $40,810 |
| 2025 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | EPIGENETIC DRIFT OF THE AGING HEART IN DROSOPHILA - PROJECT SUMMARY AGING IS A COMPLEX PROCESS ACCOMPANIED BY LOSS OF PROTEOSTASIS, GENOMIC INSTABILITY, DEREGUL | $0 |
| 2025 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | CHARACTERIZING THE NUCLEAR PORE COMPLEX-T CELL RECEPTOR CONNECTION | $0 |
| 2025 | Defense Health Agency | Grant or other assistance | MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 | DOES DYSTROPHIN RESTORATION REVERSE EPIGENETIC AND TRANSCRIPTIONAL PATHOGENIC FEATURES IN DUCHENNE MUSCULAR DYSTROPHY? | $0 |
| 2025 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | TARGETING NEUROINFLAMMATION IN AD WITH NOVEL CX3CR1 AGONISTS | -$288 |
| 2025 | National Institutes of Health | Grant or other assistance | TRANS-NIH RESEARCH SUPPORT 93.310 | DEFINING CHROMOSTASIS - A CANDIDATE REGULATOR OF HEALTHY AGING AND LONGEVITY | -$304 |
| 2025 | National Institutes of Health | Grant or other assistance | ORAL DISEASES AND DISORDERS RESEARCH 93.121 | EXPLORATORY THERAPY FOR THE SKELETAL/DENTAL PHENOTYPE IN PHOSPHO1 DEFICIENCY - +:DDF6 ?@?DA64:7:4 2=<2=:?6 A9@DA92E2D6 +&( 2?5 ( '*( ' 2C6 EH@ >2EC:I G6D:4=6D % | -$920 |
| 2025 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | A NOVEL ROLE FOR THE UPR COMPONENT, ATF6 IN AD-ASSOCIATED NEUROPROTECTIVE PATHWAYS | -$2,407 |
| 2025 | National Institutes of Health | Grant or other assistance | RESEARCH INFRASTRUCTURE PROGRAMS 93.351 | BECKMAN COULTER BIOMEK I7 HYBRID AUTOMATED WORKSTATION - PROJECT SUMMARY SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE (SBP) HAS 40 RESEARCH LABS SPECIALIZ | -$8,737 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | THE ROLE OF THE CCR4-NOT COMPLEX IN THE REGULATION OF NUCLEAR PORE COMPLEX ASSEMBLY - PROJECT SUMMARY CANCER CONTINUES TO BE A LEADING CAUSE OF DEATH WORLDWIDE | -$11,169 |
| 2025 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | NEW DOWN SYNDROME BRAIN ORGANIZATION REVEALED BY SINGLE-CELL GENOMICS - PROJECT SUMMARY/ABSTRACT NEARLY 100% OF DOWN SYNDROME (DS; TRISOMY OF HUMAN CHROMOSOME 2 | -$14,012 |
| 2025 | National Aeronautics and Space Administration | Grant or other assistance | SCIENCE 43.001 | OUR STUDIES WILL USE THE FRUIT FLY DROSOPHILA AND THE WORM C. ELEGANS TO IDENTIFY CONSERVED MECHANISMS UNDERLYING THE OXIDATIVE STRESS RESPONSE TO ALTERED GRA | -$20,000 |
| 2025 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | DISCOVERY AND DEVELOPMENT OF APOE4 CORRECTORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE - PROJECT SUMMARY ALZHEIMER'S DISEASE (AD) IS A MAJOR PUBLIC HEALTH CRISI | -$34,740 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER RESEARCH MANPOWER 93.398 | CANCER TARGETS AND DRUG DISCOVERY | -$92,536 |
| 2024 | National Institutes of Health | Grant or other assistance | CANCER CENTERS SUPPORT GRANTS 93.397 | CANCER CENTER SUPPORT GRANT | $4,081,820 |
| 2024 | National Institutes of Health | Grant or other assistance | DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS 93.279 | SAFETY/TOXICOLOGY, ADME AND CMC ACTIVITIES TO SUPPORT THE ASSESSMENT OF THE MGLU2 PAM SBP-9330 IN A PHASE 2 CLINICAL STUDY IN SMOKERS - PROJECT SUMMARY THIS RES | $3,331,239 |
| 2024 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | FRAGMENT-BASED DISCOVERY OF STEP MODULATORS IN ALZHEIMER'S DISEASE ADMINISTRATIVE SUPPLEMENT - PROJECT SUMMARY STRIATAL-ENRICHED TYROSINE PHOSPHATASE (STEP) IS | $2,835,382 |
| 2024 | National Institutes of Health | Grant or other assistance | TRANS-NIH RESEARCH SUPPORT 93.310 | SPATIAL MAPPING SENESCENT CELLS ACROSS THE MOUSE LIFESPAN BY MULTIPLEX TRANSCRIPTOMICS AND EPIGENOMICS - PROJECT SUMMARY CELLULAR SENESCENCE, CHARACTERIZED BY S | $2,690,250 |
| 2024 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | PROTEIN GLYCOSYLATION IN THE COAGULOPATHY AND INFLAMMATION OF SEPSIS | $2,622,490 |
| 2024 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | AGING AS A RISK FACTOR AND TARGET FOR PREVENTION OF LIVER CANCER - PROJECT SUMMARY – OVERALL THE INCIDENCES OF LIVER CANCER (PRIMARILY HEPATOCELLULAR CARCINOMA | $2,585,444 |
| 2024 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | ROLE OF HYPERNUTRITION AND METABOLIC STRESS IN NON-ALCOHOLIC STEATOHEPATITIS (NASH) DRIVEN HEPATOCELLULAR CARCINOMA (HCC) - PROJECT SUMMARY – OVERALL HEPATOCELL | $2,397,277 |
| 2024 | National Institutes of Health | Grant or other assistance | DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS 93.279 | DEVELOPMENT OF SBI-553, AN ALLOSTERIC MODULATOR OF NTR1, FOR THE TREATMENT OF SUBSTANCE USE DISORDERS - PROJECT SUMMARY OPIOID USE DISORDER (OUD) IS A MAJOR PUB | $1,348,795 |
| 2024 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | REWIRED SIGNALING AT THE NEXUS OF MELANOMA METASTASIS AND RESISTANCE - SUMMARY THIS R35 FOCUSES ON NOVEL MECHANISMS UNDERLYING CONTROL OF KEY UPR COMPONENTS THA | $1,170,000 |
| 2024 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | ALTERED REVERSE TRANSCRIPTASE-DEPENDENT GENE DIVERSIFICATION MECHANISMS IN ALZHEIMER'S DISEASE BRAINS | $929,705 |
| 2024 | National Institutes of Health | Grant or other assistance | TRANS-NIH RESEARCH SUPPORT 93.310 | TRANSFORMATIVE RESEARCH ON SOMATIC GENE RECOMBINATION IN THE NORMAL AND ALZHEIMER'S DISEASE-RELATED DEMENTIA BRAIN | $924,514 |
| 2024 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | DISCOVERY AND OPTIMIZATION OF APOE4 CORRECTORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE - PROJECT SUMMARY ALZHEIMER'S DISEASE (AD) IS A MAJOR PUBLIC HEALTH CRIS | $919,106 |
| 2024 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | DISCOVERY AND DEVELOPMENT OF APOE4 CORRECTORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE - PROJECT SUMMARY ALZHEIMER'S DISEASE (AD) IS A MAJOR PUBLIC HEALTH CRISI | $881,443 |
| 2024 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | PRECLINICAL DISCOVERY OF NOVEL FARNESYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND RELATED TAUOPATHIES - PROJECT SUMMARY ALZHEIMER’S DI | $878,176 |
| 2024 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | NOVEL NEUROPROTECTIVE ROLES FOR THE ALZHEIMER'S DISEASE RISK GENE SORLA IN TAU PATHOLOGY AND PATHOGENESIS - NUMEROUS MUTATIONAL VARIANTS IN THE SORLA (SORL1) GE | $867,695 |
| 2024 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | GENETIC CONTROL OF THE HEART BY TINMAN AND NEUROMANCER | $822,148 |
| 2024 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | NEW CONGENITAL DISORDERS OF GLYCOSYLATION: THERAPY AND MODELS | $809,566 |
| 2024 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | DISCOVERY OF POTENT SELECTIVE INHIBITORS OF THE HISTONE METHYLTRANSFERASE SUV39H1 FOR THE TREATMENT OF CANCER - PROJECT SUMMARY CANCER TREATMENT HAS BEEN TRANSF | $809,234 |
| 2024 | National Institutes of Health | Grant or other assistance | ALCOHOL RESEARCH PROGRAMS 93.273 | OPTIMIZATION OF DRUG-LIKE PROPERTIES OF CRFBP-CRF2 NEGATIVE ALLOSTERIC MODULATORS FOR ALCOHOL USE DISORDER - PROJECT SUMMARY THIS APPLICATION, “OPTIMIZATION OF | $800,043 |
| 2024 | National Institutes of Health | Grant or other assistance | MENTAL HEALTH RESEARCH GRANTS 93.242 | A PHARMACOCHAPERONE-BASED STRATEGY FOR IDENTIFYING CHEMICAL PROBES OF BRAIN-DERIVED ORPHAN GPCRS | $785,074 |
| 2024 | National Aeronautics and Space Administration | Grant or other assistance | SCIENCE 43.001 | OUR STUDIES WILL USE THE FRUIT FLY DROSOPHILA AND THE WORM C. ELEGANS TO IDENTIFY CONSERVED MECHANISMS UNDERLYING THE OXIDATIVE STRESS RESPONSE TO ALTERED GRA | $767,134 |
| 2024 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | COMPARATIVE RESISTOMICS OF GRAM-NEGATIVE BACTERIAL PATHOGENS - ABSTRACT INCREASING ANTIBIOTIC RESISTANCE NECESSITATES EXPANDING RESEARCH INTO THE MECHANISMS BY | $733,500 |
| 2024 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | IMPROVING PROINSULIN FOLDING TO AMELIORATE TYPE II DIABETES - PROJECT SUMMARY DIABETES IS AMONG THE FASTEST GROWING HEALTH CHALLENGES OF THE 21ST CENTURY, AFFEC | $730,079 |
| 2024 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | GCDH ADDICTION IN MELANOMA - PROJECT SUMMARY IN THIS REVISED R01 APPLICATION WE PROPOSE TO CHARACTERIZE A NOVEL MECHANISM UNDERLYING THE CONTROL OF APOPTOSIS BY | $699,580 |
| 2024 | Defense Health Agency | Grant or other assistance | MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 | SELECTIVE TARGETING OF MUTANT SHP2 ONCOPROTEINS IN RARE LEUKEMIAS | $682,472 |
| 2024 | National Institutes of Health | Grant or other assistance | ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 | MECHANISMS THAT COUPLE IRREGULAR DEVELOPMENT OF FETAL MELANOBLASTS TO PREMATURE EXHAUSTION OF ADULT MELANOCYTE STEM CELLS - PROJECT SUMMARY MAINTENANCE OF TISSU | $676,107 |
| 2024 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | REWIRING T CELL EXHAUSTION WITH IMMUNE CHECKPOINT BLOCKADE THERAPY - PROJECT SUMMARY THE GOAL OF THIS PROJECT IS TO DETERMINE WHETHER IT IS POSSIBLE TO PROMOTE | $674,996 |
| 2024 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | DISSECTING THE INTRACELLULAR AND EXTRACELLULAR ROLE OF TREM2 IN THE PATHOGENESIS OF NON-ALCOHOLIC STEATOHEPATITIS. - ABSTRACT: NON-ALCOHOLIC STEATOHEPATITIS (NA | $661,236 |
| 2024 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | CHARACTERIZING THE NUCLEAR PORE COMPLEX-T CELL RECEPTOR CONNECTION | $653,587 |
| 2024 | National Institutes of Health | Grant or other assistance | ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 | EPIGENETICS & SIGNALING IN HESC COMMITMENT AND DIFFERENTIATION INTO MUSCLE | $636,717 |
| 2024 | National Institutes of Health | Grant or other assistance | ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 | ROLE OF FBXW7-MEDIATED PROTEASOMAL DEGRADATION IN MYOFIBERS IN DETERMINING MUSCLE STEM CELL POOL SIZE | $631,857 |
| 2024 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | EPHA2 RECEPTOR SIGNALING IN BREAST CANCER MECHANOTRANSDUCTION - SUMMARY MECHANICAL FORCES GENERATED BY A RIGID EXTRACELLULAR MATRIX (ECM) IN THE TUMOR MICROENVI | $620,121 |
| 2024 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | INVESTIGATION OF ECDNA AS A DRIVER OF INTRATUMORAL HETEROGENEITY AND TREATMENT RESISTANCE IN HIGH-RISK MEDULLOBLASTOMA - THE OVERALL OBJECTIVE OF THIS PROPOSAL | $617,669 |
| 2024 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | DISCOVERY OF NOVEL INHIBITORS TARGETING TRANS-GOLGI NETWORK ACIDIFICATION IN PANCREATIC CANCER - PROJECT SUMMARY PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) IS PRO | $612,825 |
| 2024 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | OVERRIDING THE IMMUNE EVASION TACTICS OF CORONAVIRUS | $601,563 |
| 2024 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | OPTIMIZATION OF FIBROBLAST-SELECTIVE INHIBITORS OF YAP/TAZ AS NOVEL THERAPEUTICS FOR PULMONARY FIBROSIS - PROJECT SUMMARY IDIOPATHIC PULMONARY FIBROSIS IS A CHR | $596,061 |
| 2024 | National Institutes of Health | Grant or other assistance | RESEARCH INFRASTRUCTURE PROGRAMS 93.351 | BECKMAN COULTER BIOMEK I7 HYBRID AUTOMATED WORKSTATION - PROJECT SUMMARY SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE (SBP) HAS 40 RESEARCH LABS SPECIALIZ | $594,187 |
| 2024 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | HORMETIC REGULATION OF AUTOPHAGY IN AGING - PROJECT SUMMARY AUTOPHAGY DEGRADES CYTOSOLIC MATERIAL, SUCH AS AGGREGATED PROTEINS, VIA THE FORMATION OF AUTOPHAGOSO | $586,599 |
| 2024 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | MICROGLIAL HEPARAN SULFATE IN THE MODULATION OF APOE FUNCTION AND NEURODEGENERATION - HEPARAN SULFATE (HS), A SULFATED GLYCAN EXPRESSED AT THE CELL SURFACE AND | $580,960 |
| 2024 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | DISCOVERY OF GLUTARYL-COA DEHYDROGENASE INHIBITORS FOR MELANOMA AND PANCREATIC CANCER - PROJECT SUMMARY MELANOMA IS AN EXTREMELY AGGRESSIVE CANCER WITH HIGH MOR | $577,198 |
| 2024 | Defense Health Agency | Grant or other assistance | MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 | METABOLIC INTERVENTIONS TO HALT PANCREATIC CANCER | $571,350 |
| 2024 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | MACROPINOCYTOSIS INHIBITION AS A GLUTAMINE MIMETIC SENSITIZATION STRATEGY IN PANCREATIC CANCER - PROJECT SUMMARY PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) CELLS D | $561,077 |
| 2024 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | REGULATION AND FUNCTION OF STROMAL MACROPINOCYTOSIS IN PANCREATIC DUCTAL ADENOCARCINOMA - PROJECT SUMMARY RECENT YEARS HAVE WITNESSED AN APPRECIATION OF THE ROL | $556,513 |
| 2024 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | FUNCTION AND MECHANISM OF THE HIPPO-PI5P4K AXIS FOR GROWTH CONTROL - PROJECT SUMMARY OUR LONG-TERM GOAL IS TO DECIPHER THE MOLECULAR MECHANISMS UNDERLYING PI5P4 | $555,975 |
| 2024 | National Institutes of Health | Grant or other assistance | TRANS-NIH RESEARCH SUPPORT 93.310 | DEFINING CHROMOSTASIS - A CANDIDATE REGULATOR OF HEALTHY AGING AND LONGEVITY | $514,488 |
| 2024 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | MOLECULAR MECHANISMS UNDERLYING THE ASSEMBLY OF THE HUMAN PROTEASOME AND ENDOGENOUS PROTEIN COMPLEXES - PROJECT SUMMARY ADVANCES IN STRUCTURAL BIOLOGY TECHNIQUE | $487,500 |
| 2024 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | REGULATION OF BLOOD GLYCOPROTEINS BY LECTIN RECEPTORS IN HEALTH AND DISEASE - SUMMARY THE COMPOSITION OF THE BLOOD PROTEOME PROVIDES INDICATIONS OF NORMAL HEALT | $487,500 |
| 2024 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | PROTEIN SIALYLATION AND DE-SIALYATION IN CELL SURFACE GLYCOPROTEIN HOMEOSTASIS AND DISEASE - SUMMARY PROTEIN SIALYLATION IS A POST-TRANSLATIONAL MODIFICATION PR | $487,500 |
| 2024 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | DISCOVERY OF SMALL MOLECULE REGULATORS OF ATRIAL CARDIOMYOCYTE ACTION POTENTIAL DURATION TO RESTORE NORMAL CARDIAC RHYTHM IN ATRIAL FIBRILLATION - PROJECT SUMMA | $487,500 |
| 2024 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | LIGAND FUNCTIONAL SELECTIVITY IN EPHA2 RECEPTOR SIGNALING | $484,417 |
| 2024 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | UBIQUITIN D AS A POTENTIAL THERAPEUTIC TARGET FOR NASH, HCC AND CHRONIC KIDNEY DISEASES - ABSTRACT: NON-ALCOHOLIC STEATOHEPATITIS (NASH), AN ADVANCED FORM OF NO | $480,000 |
| 2024 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | GLYCOSYLTRANSFERASE FUNCTION IN DEVELOPMENT AND DISEASE | $468,000 |
| 2024 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | REGULATION OF NUTRIENT STRESS-INDUCED MACROPINOCYTOSIS IN PANCREATIC DUCTAL ADENOCARCINOMA | $442,829 |
| 2024 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | CYTOPLASMIC CHROMATIN FRAGMENTS IN CELL SENESCENCE - NOVEL MECHANISMS AND INTERVENTIONS - PROJECT SUMMARY CELLULAR SENESCENCE IS A CAUSE OF CELL AND TISSUE AGIN | $428,501 |
| 2024 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | MOLECULAR PATHOGENESIS OF AF10-REARRANGED LEUKEMIAS - PROJECT SUMMARY THERE HAS BEEN CONSIDERABLE PROGRESS IN THE LAST FEW YEARS IN THE CHARACTERIZATION OF MOLE | $427,097 |
| 2024 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | NON-CANONICAL PHOSPHATIDYLINOSITOL KINASES IN TRIPLE NEGATIVE BREAST CANCER | $423,760 |
| 2024 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | TARGETING THE FBXO44/SUV39H1 PATHWAY IN CANCER - PROJECT SUMMARY REPETITIVE ELEMENTS (RES) COMPOSE ~45% OF THE HUMAN GENOME AND ARE NORMALLY TRANSCRIPTIONALLY S | $423,760 |
| 2024 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | TARGETING ER+ BREAST CANCER THROUGH INDUCED VIRAL MIMICRY - PROJECT SUMMARY REPETITIVE ELEMENTS (RES) COMPOSE ~45% OF THE HUMAN GENOME AND ARE NORMALLY TRANSCRI | $423,760 |
| 2024 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | AUGMENTED NOTCH SIGNALING AS A THERAPEUTIC APPROACH FOR ALAGILLE SYNDROME - PROJECT SUMMARY ALAGILLE SYNDROME (ALGS) IS AN AUTOSOMAL DOMINANT DISORDER CHARACTER | $411,840 |
| 2024 | National Institutes of Health | Grant or other assistance | VISION RESEARCH 93.867 | RETINOIC ACID TARGET GENES AND TRANSCRIPTIONAL MECHANISMS DURING EYE DEVELOPMENT - PROJECT SUMMARY ONE OF THE MOST CRITICAL FUNCTIONS OF THE VITAMIN A (RETINOL) | $390,000 |
| 2024 | Defense Health Agency | Grant or other assistance | MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 | WHITE ADIPOSE TISSUE SURROUNDING LYMPH NODES MODULATES ANTIMELANOMA IMMUNITY MODIFICATION P00001 TRANSFERRED AWARD TO CEDARS SINAI MEDICAL CENTER | $314,470 |
| 2024 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | EPIGENETIC REPROGRAMMING TO COUNTERACT NEURONAL AGING AND DEGENERATION - PROJECT SUMMARY/ABSTRACT THE AGING BRAIN IS INCREASINGLY SUSCEPTIBLE TO COGNITIVE DECLI | $248,999 |
| 2024 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | THE AGING PANCREAS AS A PRO-TUMORIGENIC NICHE - PROJECT SUMMARY AGE IS A MAJOR RISK FACTOR FOR PANCREATIC DUCTAL ADENOCARCINOMA (PDAC), WITH THE INCIDENCE OF PD | $243,750 |
| 2024 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | SPATIAL REGULATORS OF SKELETAL MUSCLE REGENERATION AND DISEASE - SKELETAL MUSCLES ARE RESPONSIBLE FOR MOVEMENT, BREATHING, POSTURE AND METABOLISM. LOSS OF MUSCL | $241,260 |
| 2024 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | DEVELOPMENT AND IMPLEMENTATION OF ADVANCED TECHNOLOGIES FOR CANCER METABOLISM RESEARCH - PROJECT SUMMARY THIS PROPOSAL REQUESTS SUPPORT FOR MY POSITION AS THE D | $142,032 |
State business registration
- SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE CA, Employee benefit plan sponsor (Form 5500), Filed for plan year 2025
- SANFORD-BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, INC. FL, Foreign nonprofit corporation (FORNP), Inactive, formed 2006-10-10
The same business name in the same state, from the state’s official registry data.
Patents
101 US patents filed in the last 20 years.
- Sanford Burnham Prebys Medical Discovery Institute 101 patents, 2015-11-10 to 2026-09-22 EXACT high confidence: identical full name and state
| Patent | Title | Granted | Source |
|---|---|---|---|
| US 12741940 | Dopamine receptor d1 agonists and methods of use | 2026-09-22 | PTBLXML, file of 2026-09-22 |
| US 12729208 | Inhibitor of apoptosis (IAP) protein antagonists | 2026-09-08 | PTBLXML, file of 2026-09-08 |
| US 12708673 | Methods and compositions related to peptides and proteins with c-terminal elements | 2026-08-18 | PTBLXML, file of 2026-08-18 |
| US 12678509 | Inhibitor of apoptosis (IAP) protein antagonists | 2026-07-14 | PTBLXML, file of 2026-07-14 |
| US 12643910 | Substituted pyrazolo[3,4-b]pyridines as ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) modulators | 2026-06-02 | PTBLXML, file of 2026-06-02 |
| US 12637436 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | 2026-05-26 | PTBLXML, file of 2026-05-26 |
| US 12594277 | Macrocyclic ULK1/2 inhibitors | 2026-04-07 | PTBLXML, file of 2026-04-07 |
| US 12590336 | Role of PVT1 in the diagnosis and treatment of MYC-driven cancer | 2026-03-31 | PTBLXML, file of 2026-03-31 |
| US 12534729 | Uses of synthetic lethal partners for treatment of cancer | 2026-01-27 | PTBLXML, file of 2026-01-27 |
| US 12516085 | Methods and compositions for treating Myc-driven cancers | 2026-01-06 | PTBLXML, file of 2026-02-13 |
The newest patents of the PatentsView assignees above, matched to this record by name (and state).
Trademarks
2 US trademarks, 0 live.
- SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE 2 marks, CA EXACT high confidence: identical full name and state
| Mark | Serial | Filed | Status | Source |
|---|---|---|---|---|
| SBP | 87014711 | 2016-04-26 | Registration cancelled | TRCFECO2, file of 2024-03-27 |
| SCIENCE BENEFITING PATIENTS | 87014699 | 2016-04-26 | Registration cancelled | TRCFECO2, file of 2024-03-27 |
The newest marks of the trademark owners above, matched to this record by name (and state).
In the news
2,073 news articles name this organization (June 2015 to November 2026); the latest 10:
- New light-based tool reveals how cells regulate autophagy
news-medical.net, November 13, 2026 - Light-controlled tool halts cellular recycling to offer disease mechanism clues
eurekalert.org, November 12, 2026 - Photo Gallery: Sanford Burnham Prebys' Illumination Gala 2026
sandiegomagazine.com, October 26, 2026 - News Nuggets: Endangered list, ArtsConnect prize, Curebound Cancer Challenge, more
sandiegouniontribune.com, October 14, 2026 - Opinion: We need Prop. 38 to fund urgently needed medical research
pressdemocrat.com, October 5, 2026 - Opinion: We need Prop. 38 to fund urgently needed medical research
sandiegouniontribune.com, October 1, 2026 - In Photos: The Country Friends' Art of Fashion
sandiegomagazine.com, September 21, 2026 - 8 Charitable Events to Attend in October | San Diego Magazine
sandiegomagazine.com, September 17, 2026 - Scientists Say Your Organs Age in Two Sudden Bursts
popularmechanics.com, September 16, 2026 - Targeted News Service
targetednews.com, September 11, 2026
News article metadata and links: The GDELT Project (https://www.gdeltproject.org/). Matched by: Exact name match: "sanford burnham prebys medical discovery institute". A shared name is not proof of the same organization; how the matching works. Most in the news.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | Sanford Burnham Prebys Medical Discovery Institute | CA | State business registries | name and state |
| Business registration | Sanford Burnham Prebys Medical Discovery Institute | CA | State business registries | name and state |
| Business registration | SANFORD-BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, INC. | FL | State business registries | EIN (EXACT, as the state registration reports it) |
| College | Sanford Burnham Prebys Medical Discovery Institute | CA | Colleges and universities (IPEDS) | name and state |
| Plan sponsor | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE | CA | Form 5500 (employee benefit plans) | EIN (EXACT) |
| Federal award recipient | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE | CA | Federal spending (USAspending) | name and state |
| Patent assignee | Sanford Burnham Prebys Medical Discovery Institute | CA | Patents (USPTO) | name and state |
| Trademark owner | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE | CA | Trademarks (USPTO) | name and state |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
NTEE code Biomedicine, Bioengineering Research, CA first:
- RESMED SLEEP DISORDERED BREATHING FOUNDATION CA
- FOGARTY INSTITUTE FOR INNOVATION CA
- GENE THERAPY INSTITUTE FOR HISPANIC CA
- GARY AND MARY WEST HEALTH INSTITUTE CA
- SOUTHERN CALIFORNIA INSTITUTE FOR RESEARCH AND EDUCATION CA
- SCRIPPS RESEARCH INSTITUTE CA
- TRIBE RESEARCH CA
- PEDIATRIC MOONSHOT INC CA
- OPENLABS CA
- BIOMEDICAL RESEARCH INSTITUTE OF SOUTHERN CALIFORNIA CA
In other datasets, the same topic (Medical research) in CA:
- Form D issuer: 4D Molecular Therapeutics Inc (Form D private offerings)
Interests: Biomedicine, Bioengineering Research · abuse:substance · men:issues · science:research_education · space:outer · survivor:cancer · Medical research
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Census Tract 83.12, San Diego County, California, county San Diego County, CA, state California; placed by its ZIP code. The tract is the tract holding most of the record's ZIP code (FURP does not geocode street addresses).
- DAVID BRENNER was paid $1,345,526, 12.7 times the median household income in San Diego County, CA ($106,268), where 10.3% of residents live in poverty.
- Revenue of $114,401,821 is $35 per resident of San Diego County, CA (population 3,288,774).
- That revenue equals 0.09% of all household income in San Diego County, CA (1,171,278 households at the median $106,268, about $124,469,370,504).
- 611 employees is 0.2 per 1,000 residents of San Diego County, CA.
| Measure | Census tract Census Tract 83.12, San Diego County, California | County San Diego County, CA | State California |
|---|---|---|---|
| Population B01003 | 4,147 | 3,288,774 | 39,287,377 |
| Population, 2020 census P1 | 3,787 | 3,298,634 | 39,538,223 |
| Median age B01002 | 45.5 | 37.3 | 37.9 |
| Under 18 B01001 | 15.6% | 20.9% | 22.0% |
| 65 and over B01001 | 28.1% | 15.4% | 15.7% |
| Households B11001 | 1,677 | 1,171,278 | 13,548,091 |
| Foreign born B05002 | 26.6% | 22.8% | 27.0% |
| Median household income B19013 | $143,847 | $106,268 | $99,122 |
| Median family income B19113 | $197,625 | $122,377 | $113,346 |
| Per capita income B19301 | $91,044 | $51,976 | $49,513 |
| Poverty rate B17001 | 8.4% | 10.3% | 12.0% |
| Unemployment rate B23025 | 5.4% | 6.1% | 6.6% |
| Civilian labor force B23025 | 1,863 | 1,689,384 | 20,068,466 |
| Mean commute (minutes) B08013 | 18.1 | 25.5 | 28.7 |
| Bachelor's degree or higher B15003 | 71.5% | 43.2% | 37.1% |
| Housing units B25001 | 1,922 | 1,250,641 | 14,644,735 |
| Owner-occupied B25003 | 69.4% | 54.6% | 55.9% |
| Renters B25003 | 30.6% | 45.4% | 44.1% |
| Median home value B25077 | $2,000,001 | $854,700 | $734,700 |
| Median gross rent B25064 | $2,384 | $2,246 | $2,036 |
| White, not Hispanic B03002 | 63.3% | 42.4% | 33.8% |
| Black B03002 | 0.2% | 4.4% | 5.2% |
| Hispanic or Latino B03002 | 19.4% | 34.6% | 40.2% |
| Asian B03002 | 11.1% | 12.1% | 15.3% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Census Tract 83.12, San Diego County, California.
Comments